[
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 3-day history of cough, fever, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). According to the guidelines, which of the following should be used, in addition to clinical judgment, to determine the need for hospitalization?",
    "options": [
      "CURB-65 score only",
      "Pneumonia Severity Index (PSI) preferentially over CURB-65",
      "Serum procalcitonin levels only",
      "Influenza virus testing only"
    ],
    "correct_answer_text": "Pneumonia Severity Index (PSI) preferentially over CURB-65",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly states that clinicians should use a validated clinical prediction rule for prognosis, recommending the Pneumonia Severity Index (PSI) preferentially over the CURB-65 to determine the need for hospitalization in adults diagnosed with community-acquired pneumonia (CAP). This aligns directly with the question's requirement for an adjunct to clinical judgment in assessing hospitalization needs.",
    "reasoning_ground_truth": "The guidelines for CAP recommend using a validated clinical prediction rule for prognosis, **preferentially the Pneumonia Severity Index (PSI) over the CURB-65**, in addition to clinical judgment to determine the need for hospitalization [1]. Serum procalcitonin levels are used to determine initiation of antibiotics, and influenza testing is for identifying the presence of influenza virus but not for determining hospitalization [1, 2].",
    "context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nThe 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency department settings and are electronically calculable (51, 61). Several groups have validated these criteria in pneumonia cohorts from different countries (57\u201359, 61), with a meta-analysis reporting one\nOur recommendation to use the PSI as an adjunct to clinical judgment to guide the initial site of treatment is based on consistent evidence of the effectiveness and safety of this approach. Using a safe and effective decision aid to increase outpatient treatment of patients with CAP has potential to decrease unnecessary variability in admission rates, the high cost of inpatient pneumonia treatment (53, 54), and the risk of hospital-acquired complications.\nThis document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.\nFor adults with community-acquired pneumonia (CAP) at risk for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):",
    "ground_truth_context": "In addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age >65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP. [1]",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension presents for a routine follow-up. Her eGFRcr is 40 mL/min/1.73 m2. Which of the following is the most appropriate next step in evaluating her kidney function?",
    "options": [
      "Measure cystatin C to calculate eGFRcr-cys",
      "Proceed directly to measuring GFR using an exogenous filtration marker",
      "Repeat eGFRcr in 3 months",
      "No additional testing is needed"
    ],
    "correct_answer_text": "Measure cystatin C to calculate eGFRcr-cys",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that the first method to evaluate GFR should be eGFRcr, and if greater accuracy is needed, the next step is to measure eGFRcr-cys. Since the patient has a significantly low eGFRcr of 40 mL/min/1.73 m\u00b2, measuring cystatin C to calculate eGFRcr-cys is the most appropriate next step for a more accurate evaluation of her kidney function. Options B, C, and D do not align with the recommended approach for further evaluation in this scenario.",
    "reasoning_ground_truth": "According to the CKD guidelines, the initial test for GFR evaluation is eGFRcr. If the eGFRcr is thought to be inaccurate, a more accurate assessment of GFR is needed. In such cases, cystatin C should be measured to estimate eGFRcr-cys.  If eGFRcr-cys is inaccurate, then mGFR can be considered [3, 4].",
    "context": "In this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers. In contrast to the previous\nstability and a subsequent progression in CKD in adolescence or adulthood is common. Given the long life expectancy of children, follow-up plans must take into account the risk of late CKD or kidney failure. Healthy children and adolescents should have excellent kidney function, so an estimated eGFR under 90 ml/min per 1.73 m\u00b2 (CKD G2\u2013G5) represents decreased kidney function in these age groups. Early assessment and intervention of children with CKD is crucial to maximize overall health across\nThe KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommended \u201cto report eGFRcr in adults using the 2009 CKD-EPI creatinine equation. An alternative creatinine-based GFR estimating equation is acceptable if it has been shown to improve accuracy of GFR estimates compared to the 2009 CKD-EPI creatinine equation.\u201d We are updating this recommendation to accommodate the availability of alternative equations that also have high levels of accuracy.\nMeasure eGFRcr-cys if not performed and available  \nStage according to GFR and ACR  \nEstablish underlying cause  \nEstimate risk of progression  \nInitiate treatment  \nCKD not present  \nTiming of retesting based on individual characteristics such as risk of progression\nPractice Point 2.1.1: Assess albuminuria in adults, or albuminuria/proteinuria in children, and GFR at least annually in people with CKD.  \nPractice Point 2.1.2: Assess albuminuria and GFR more often for individuals at higher risk of CKD progression when measurement will impact therapeutic decisions.  \nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.",
    "ground_truth_context": "The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel. If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated. [3] eGFRcr-cys provides the most accurate estimate and is recommended as the primary supportive test for people in whom there are concerns about eGFRcr accuracy [4] ",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with a history of a recent acute coronary syndrome (ACS) is currently on dual antiplatelet therapy (DAPT). He is now 18 months post-ACS and has had no recurrent events. What is the recommended approach for his DAPT?",
    "options": [
      "Continue DAPT for another 12 months.",
      "Transition to single antiplatelet therapy.",
      "Discontinue all antiplatelet therapy",
      "Add a third antiplatelet agent"
    ],
    "correct_answer_text": "Transition to single antiplatelet therapy.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that in patients with acute coronary syndrome (ACS) treated with dual antiplatelet therapy (DAPT), P2Y12 inhibitor therapy should be continued for at least 12 months. Since the patient is now 18 months post-ACS and has had no recurrent events, transitioning to single antiplatelet therapy is the recommended approach after the initial 12-month period of DAPT. Therefore, option B is directly supported by the context.",
    "reasoning_ground_truth": "According to the guidelines, patients with a history of ACS >1 year prior who have remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD). The document focuses on the duration of DAPT and suggests that the relevant sections in the guidelines be updated to reflect a transition to single antiplatelet therapy for these patients after one year, [5].",
    "context": "Colors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, P2Y12 inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months (52,71,140,141).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|IIb|ASR|In patients with ACS (NSTE-ACS or STEMI) treated with coronary stent implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 12 months may be reasonable (16,22\u201326,28,30,40,41,43,53,54,72).|\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after BMS or DES implantation, P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) should be given for at least 12 months (16,50\u201355,72,96\u201398).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS treated with DAPT after BMS or DES implantation, P2Y12 inhibitor therapy (clopidogrel, prasugrel, or ticagrelor) should be given for at least 12 months (16,50\u201355,72,96\u201398).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|",
    "ground_truth_context": "patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.  This focused update is designed to function both as a standalone document and to serve as an update to the relevant sections on duration of DAPT in the 6 clinical practice guidelines, replacing relevant text, figures, and recommendations. [5]",
    "is_correct": true
  },
  {
    "question": "A 35-year-old female presents with a 5-day history of nasal congestion, facial pain, and purulent nasal discharge. She reports no improvement with over-the-counter decongestants. According to the guidelines, what is the appropriate initial management strategy?",
    "options": [
      "Immediate antibiotic therapy",
      "Watchful waiting without antibiotics",
      "Intranasal corticosteroids",
      "Referral to an otolaryngologist"
    ],
    "correct_answer_text": "Watchful waiting without antibiotics",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that there are no randomized controlled trials (RCTs) specifically studying the efficacy of decongestants for acute bacterial rhinosinusitis (ABRS), and it suggests that management of certain conditions, including rhinosinusitis, may not require immediate antibiotic therapy. The guidelines imply that watchful waiting is an appropriate strategy, especially since the patient has only had symptoms for 5 days and has not shown improvement with over-the-counter decongestants. Therefore, option B, watchful waiting without antibiotics, aligns with the context provided.",
    "reasoning_ground_truth": "The guidelines recommend that the initial management strategy for uncomplicated acute bacterial rhinosinusitis (ABRS) is **watchful waiting without antibiotic therapy**, regardless of severity [6]. Supportive therapies for symptom relief can also be considered [7].",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are\nhave been used to treat nasal congestion associated with the common cold for many years.103-107 There are no RCTs that specifically study the efficacy of decongestants for ABRS, but 2 small studies have shown that xylometazoline nasal spray reduces congestion of sinus and nasal mucosa on imaging studies65,108 and is superior to a single orally administered dose of pseudoephedrine.108 Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics\nxylometazoline spray was added to antibiotics for ABRS.97 Topical decongestants should not be used more than 3 to 5 consecutive days without a prolonged intervening drug-free period due to their propensity to cause rebound congestion and rhinitis medicamentosa.87\nThe guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic nonallergic rhinitis, vasomotor rhinitis, invasive fungal rhinosinusitis, allergic fungal rhinosinusitis, vascular headaches, and migraines. Similarly, the guideline will not consider management of rhinosinusitis in patients with the following modifying factors but will discuss the\n2. Saline irrigations, or washing out the nose with salt water, can relieve symptoms and remove mucus that is hard to blow out.\n3. Nasal steroid sprays can reduce symptoms after 15 days of use, but the benefit is small (about 14 people must use them to get 1 person better), and side effects include headache, nasal itching, and nosebleeds.\nDecongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.|",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline) [6]. The purpose of this statement is to encourage consideration of supportive therapies that may improve quality of life for indi-viduals with viral rhinosinusitis (VRS) and to avoid unneces-sary prescribing of antibiotics for viral disease. [7]",
    "is_correct": true
  },
  {
    "question": "A 40-year-old male presents to the emergency department with a witnessed seizure lasting 7 minutes. He has no known history of epilepsy. According to the guidelines, what is the recommended initial therapy?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Intravenous phenobarbital"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for seizures lasting more than 5 minutes, the recommended initial therapy is a benzodiazepine, specifically mentioning IM midazolam, IV lorazepam, or IV diazepam as the initial therapy of choice. Since the patient has a seizure lasting 7 minutes, IV lorazepam (option C) is one of the recommended therapies and is appropriate for this situation. Options A (IV phenytoin) and D (IV phenobarbital) are not indicated as initial therapy according to the guidelines provided. Option B (IM midazolam) is also a valid choice, but IV lorazepam is explicitly mentioned as a recommended initial therapy.",
    "reasoning_ground_truth": "For convulsive status epilepticus, the guidelines recommend that a benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is the initial therapy of choice. IM midazolam has superior effectiveness in adults when intravenous access is not established. IV Phenobarbital is an alternative, not first line [8, 9].",
    "context": "The algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy should be apparent. A benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and\nThe analysis addressed five questions involving adults/children with seizures lasting more than 5 minutes:  \n1. Which anticonvulsants are efficacious as initial and subsequent therapy?\n2. What adverse events are associated with anticonvulsant administration?\n3. Which is the most effective benzodiazepine?\n4. Is IV fosphenytoin more effective than IV phenytoin?\nThe third therapy phase should begin when the seizure duration reaches 40 minutes. There is no clear evidence to guide therapy in this phase (level U). Compared with initial therapy, second therapy is often less effective (adults\u2014level A, one class I RCT; children\u2014level C, two class III RCTs), and the third therapy is substantially less effective (adults\u2014level A).\nThe second-therapy phase should begin when the seizure duration reaches 20 minutes and should conclude by the 40-minute mark when response (or lack of response) to the second therapy should be apparent. Reasonable options include fosphenytoin (level U), valproic acid (level B, one class II study) and levetiracetam (level U). There is no clear evidence that any one of these options is better than the others. The ongoing Established Status Epilepticus Treatment Trial (ESETT) should provide the\nby itself (2). Since the majority of seizures are brief, and once a seizure lasts more than 5 minutes it is likely to be prolonged (3), status treatment protocols have used a 5-minute definition to minimize both the risk of seizures reaching 30 minutes and the adverse outcomes associated with needlessly intervening on brief, self-limited seizures (2, 4). This guideline follows this convention and, for purposes of treatment, uses the term status epilepticus to represent studies involving both",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A). A benzodiazepine (specifically IM mid-azolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice [8, 9]",
    "is_correct": false
  },
  {
    "question": "A 60-year-old female presents with a 6-month history of persistent nasal congestion and facial pressure. She has tried over-the-counter remedies with no relief. To confirm a diagnosis of chronic rhinosinusitis (CRS), which of the following is required?",
    "options": [
      "Self-reported symptoms alone",
      "Objective documentation of sinonasal inflammation",
      "Positive allergy testing",
      "CT scan of the sinuses only"
    ],
    "correct_answer_text": "Objective documentation of sinonasal inflammation",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that to confirm a clinical diagnosis of chronic rhinosinusitis (CRS), \"the clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation,\" which can be achieved through methods such as anterior rhinoscopy, nasal endoscopy, or computed tomography. This directly supports option B as the required step for diagnosis.",
    "reasoning_ground_truth": "The guidelines state that a diagnosis of CRS cannot be based on signs and symptoms alone, but also requires **objective evidence of sinonasal inflammation**, which can be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography [10, 11].",
    "context": "Symptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly sensitive for diagnosing CRS, but symptom-based criteria alone are relatively nonspecific. Diagnosing CRS requires that inflammation be documented (polyps, edema, or purulent mucus) in addition to persistent\n- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\nThe clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over harm.\nallergic rhinitis may increase susceptibility to inflammation within the nose and paranasal sinuses, thereby predisposing to rhinosinusitis. A recent retrospective cohort study of CRS determined AR as a premorbid factor in newly diagnosed CRS. Of note, most of the above studies are case series with heterogeneous inclusion criteria that suggest a link between these allergy and rhinosinusitis conditions but do not imply causality.\n|7A. Diagnosis of CRS or recurrent ARS|Clinicians should distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms.|\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed  tomography. [10] The purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation [11]",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with a new diagnosis of primary open-angle glaucoma is being educated about his condition. According to the guidelines, which of the following is most important to ensure effective patient education?",
    "options": [
      "Providing lengthy written educational material",
      "Using complex medical terminology to explain the disease",
      "Ensuring the information is clear, relevant, and accessible",
      "Relying solely on verbal explanations"
    ],
    "correct_answer_text": "Ensuring the information is clear, relevant, and accessible",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of providing education that is \"clear, relevant, and accessible\" to patients and their caregivers, particularly for those with poor health literacy skills. This aligns directly with option C, making it the most important aspect of effective patient education according to the guidelines. Options A, B, and D do not support the need for clarity and accessibility as highlighted in the context.",
    "reasoning_ground_truth": "The guidelines emphasize that ophthalmologists should strive to provide education that is **clear, relevant, and accessible** to the patient and their caregivers. Limiting dense text and using techniques such as asking patients to explain what they understand can be helpful [12].",
    "context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. Patients with higher levels of literacy may ask questions that lead to a more complex\nIt is important to educate and engage patients in the management of their condition. Patients should be educated through in-person, written, and online information about the disease process, the rationale and goals of intervention, the status of their condition, and the relative benefits and risks of alternative interventions so that they can participate meaningfully in developing an appropriate plan of action. Patients should be encouraged to alert their ophthalmologists to physical or\nIf the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be referred for and encouraged to use appropriate vision rehabilitation and social services.703 More information on vision rehabilitation, including materials for patients, is available at\nto alert their ophthalmologists to physical or emotional changes that occur when taking glaucoma medications and to barriers to self-management. Ophthalmologists should remain mindful that the diagnosis of glaucoma can itself lead to negative psychological effects and to fear of blindness.691-695\nWhen deciding to treat a patient with glaucoma, it is important to remember that the goal of treatment is to maintain the IOP within a range at which visual field loss is unlikely to substantially reduce a patient\u2019s health-related quality of life over his or her lifetime.322",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s). Patients with poor health literacy skills may be especially vulnerable to worse visual outcomes.696 Limiting dense text and using \u201cteach-back\u201d techniques such as asking patients to explain what they understand about glaucoma may be helpful for patients with limited literacy skills. [12]",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has moderate-to-high disease activity despite being treated with methotrexate. Which of the following is conditionally recommended according to the guidelines?",
    "options": [
      "Adding a biologic DMARD to methotrexate",
      "Switching to a different conventional synthetic DMARD",
      "Continuing methotrexate monotherapy",
      "Adding a targeted synthetic DMARD to methotrexate"
    ],
    "correct_answer_text": "Continuing methotrexate monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that \"Addition of a bDMARD or tsDMARD is conditionally recommended over triple therapy for patients taking maximally tolerated doses of methotrexate who are not at target.\" Since the patient has moderate-to-high disease activity despite being treated with methotrexate, adding a biologic DMARD (bDMARD) is a recommended option according to the guidelines.",
    "reasoning_ground_truth": "For patients with moderate to high disease activity, despite being treated with methotrexate, the guidelines conditionally recommend continuing methotrexate monotherapy over combining methotrexate with a biologic (bDMARD) or targeted synthetic DMARD (tsDMARD) [13].",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nHydroxychloroquine is conditionally recommended over other csDMARDs because it is better tolerated and has a more favorable risk profile in patients with RA. Sulfasalazine is conditionally recommended over methotrexate, and methotrexate is conditionally recommended over leflunomide for DMARD-naive patients with low disease activity. Methotrexate is recommended over leflunomide because of its greater dosing flexibility and lower cost.\n|Switching to a non-methotrexate DMARD is conditionally recommended over continuation of methotrexate for patients taking methotrexate with progressive subcutaneous nodules.|Very low|PICO 65|p. 428|\n|Pulmonary disease| | | |\n|Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity.|Very low|PICO 67|p. 430|\n|A minimal initial treatment goal of low disease activity is conditionally recommended over a goal of remission.|Low|PICO 13|p. 201|\n|Addition of a bDMARD or tsDMARD is conditionally recommended over triple therapy for patients taking maximally tolerated doses of methotrexate who are not at target.|Very low|PICO 19.C2\u2013C6\u2020|p. 240\u20131|\n|Methotrexate is conditionally recommended over leflunomide.|Very low|PICO 1a.C3|p. 5|",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD [13]",
    "is_correct": false
  },
  {
    "question": "A 25-year-old male is diagnosed with gonococcal urethritis.  The guidelines for treating gonorrhoea emphasize the importance of using the GRADE approach to assess the certainty of evidence. What is one way this is achieved?",
    "options": [
      "By relying solely on expert opinions.",
      "By conducting a narrative review of the literature.",
      "By assessing the quality of evidence based on risk of bias and inconsistency.",
      "By only including data from randomized controlled trials"
    ],
    "correct_answer_text": "By assessing the quality of evidence based on risk of bias and inconsistency.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context mentions that the quality of evidence for treatments of gonococcal infections is assessed, indicating that factors such as risk of bias and inconsistency are considered. This aligns with the GRADE approach, which evaluates the certainty of evidence based on these criteria. Options A, B, and D do not reflect the systematic assessment of evidence quality as described in the guidelines.",
    "reasoning_ground_truth": "The GRADE approach assesses the quality of evidence for treatment interventions using criteria for design, risk of bias, inconsistency, indirectness, imprecision, effect size, and other factors [14].",
    "context": "|Recommendations|Strength of recommendation and quality of evidence|\n|---|---|\n|Genital and anorectal gonococcal infections| |\n|Recommendation 1|Good practice statement|\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated based on local epidemiological patterns.\nThese guidelines provide evidence-based recommendations for the treatment of specific clinical conditions caused by N. gonorrhoeae. These guidelines provide direction for countries as they develop national treatment recommendations; however, national guidelines should also take into account the local pattern of AMR, as well as health service capacity and resources.\nThe objectives of these guidelines are:  \n- to provide evidence-based guidance on treatment of infection with N. gonorrhoeae; and\n- to support countries to update their national guidelines for treatment of gonococcal infection.\nThe quality of the evidence for the effects of treatments for gonococcal infections is low. Evidence is available from 108 studies, including 14 randomized and 94 non-randomized studies, which were conducted in a broad range of high-, middle- and low-income countries. Although high cure rates were shown (> 95%), the evidence is outdated and regionally specific, and therefore is considered to be indirect due to emerging resistance data. Available data on AMR in N. gonorrhoeae revealed high rates",
    "ground_truth_context": "Briefly, the GRADE approach assesses the quality of evidence for treatment interventions using well-established criteria for the design, risk of bias, inconsistency, indirectness, imprecision, effect size, dose\u2013response curve and other considerations that may affect the quality of the evidence. [14]",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male is admitted to the hospital with an acute medical illness. According to guidelines, what is the primary purpose of using a parenteral anticoagulant in this setting?",
    "options": [
      "To treat an existing deep vein thrombosis",
      "To prevent the development of venous thromboembolism (VTE)",
      "To reduce the risk of arterial thrombosis",
      "To manage acute bleeding events"
    ],
    "correct_answer_text": "To prevent the development of venous thromboembolism (VTE)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context explicitly states that the panel suggests using any parenteral anticoagulant for VTE prevention in acutely ill medical patients, indicating that the primary purpose of using these anticoagulants is to prevent the development of venous thromboembolism (VTE).",
    "reasoning_ground_truth": "The primary purpose of parenteral anticoagulation in acutely ill medical patients is to **prevent the development of VTE**, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [15].",
    "context": "Conclusions and research needs for this recommendation. The panel determined that there is low certainty in the evidence for a net health benefit from using any parenteral anticoagulant in acutely ill medical patients. Other EtD criteria were generally in favor of using any parenteral anticoagulant for VTE prevention so that the desirable consequences were greater than the undesirable consequences.  \nThe panel identified the following additional research questions:\nIn acutely ill medical patients, the ASH guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef). Among these anticoagulants, the panel suggests using LMWH (low certainty in the evidence of effects \u00c5\u00c5\u25ef\u25ef) or fondaparinux (very low certainty in the evidence of effects \u00c5\u25ef\u25ef\u25ef) rather than UFH (conditional recommendation). Remark: These 3 recommendations also apply to anticoagulant\nRecommendations 1, 2, and 3. In acutely ill medical patients, the American Society of Hematology (ASH) guideline panel suggests using UFH, LMWH, or fondaparinux rather than no parenteral anticoagulant (conditional recommendation, low certainty in the evidence of effects). Among these anticoagulants, the panel suggests using LMWH (low certainty in the evidence of effects) or fondaparinux (very low certainty in the evidence of effects) rather than UFH (conditional recommendation). Remark: These\nQuestion: Should any parenteral anticoagulant (UFH, LMWH or fondaparinux) vs no parenteral anticoagulant be used in acutely ill medical patients for VTE prophylaxis?  \nQuestion: If pharmacologic prophylaxis is used, should LMWH vs UFH be used?  \nQuestion: If pharmacologic prophylaxis is used, should fondaparinux vs LMWH or UFH be used?\n- More information on the optimal dosing of parenteral anticoagulation to prevent VTE in medical inpatients is needed. In particular, can lower or higher doses be used in different settings (perhaps dependent on baseline risk), and should dosing be adjusted in obese patients, underweight patients, and patients with renal disease?",
    "ground_truth_context": "The panel also considered the randomized controlled trial (RCT) by Cohen et al28 that compared fondaparinux against no parenteral anticoagulation and felt that the results were similar enough to include fondaparinux with UFH and LMWH. The EtD framework is shown online at https://dbep.gradepro.org/profile/ 54B577E9-7F80-3A78-B3EA-3850E9A1D432.[15]",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of smoking and hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context emphasizes the importance of managing pneumonia, particularly in patients with severe infections or those at risk, such as the 60-year-old male with a persistent cough, fever, and shortness of breath. Given the chest X-ray findings of a right lower lobe infiltrate, starting empiric antibiotic therapy for community-acquired pneumonia (CAP) is the most appropriate next step in management, as it aligns with the recommendation for longer courses of antibiotic therapy for pneumonia. Options B, C, and D do not directly address the immediate need for treatment of pneumonia as indicated by the patient's symptoms and X-ray findings.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "Given the variability of NTM lung disease severity and response to treatment, patients should be closely comanaged with an infectious disease or pulmonary specialist.\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59  \ncomplicated by meningitis, endocarditis, and other deep-seated infection; or 2) infection with other, less-common pathogens not covered in these guidelines (e.g., Burkholderia pseudomallei, Mycobacterium tuberculosis or endemic fungi).\nBefore initiating treatment, care should be taken to rule out other causes of respiratory symptoms at high altitude, such as pneumonia, viral upper respiratory tract infection, mucus plugging, bronchospasm, or myocardial infarction. Descent is the first treatment priority in persons with HAPE. If descent cannot be initiated as a result of logistical factors, supplemental oxygen or a portable hyperbaric chamber should be used. Patients who have access to oxygen (eg, a hospital or high altitude\n(>10%) of invasive PNS S pneumoniae*, those with severe infection (eg, evidence of systemic toxicity with temperature of 39\u00b0C [102\u00b0F] or higher, and threat of suppurative complications), age >65 years, recent hospitalization, antibiotic use within the past month, or those who are immunocompromised.125\npatients at risk of HE or with profound metabolic disarray, because of the high risk of neurological deterioration, aspiration and poor compliance. Regular chest physiotherapy should be carried out and ventilator associated pneumonia avoided (evidence level III, grade of recommendation 1).",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that for most people and clinical settings, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing (Practice Point 4.2.2). Since the patient's eGFR is based on serum creatinine and falls within the recommended guidelines for dosing medications, option A is the most appropriate approach. Options B, C, and D are not supported by the context provided.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Practice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]).\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]) (1B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nRecommendation 3.15.1.1: In adults aged \u226550 years with eGFR <60 ml/min per 1.73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3a\u2013G5), we recommend treatment with a statin or statin/ezetimibe combination (1A).  \nRecommendation 3.15.1.2: In adults aged \u226550 years with CKD and eGFR \u226560 ml/min per 1.73 m2 (GFR categories G1\u2013G2), we recommend treatment with a statin (1B).",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context specifies that in adults with convulsive status epilepticus and without established IV access, intramuscular midazolam is recommended as the initial therapy of choice due to its superior effectiveness compared to IV lorazepam. Since the patient has a seizure lasting 7 minutes and IV access is difficult to obtain, intramuscular midazolam is the preferred treatment.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "The algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy should be apparent. A benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and\nThe optimal pharmacologic treatment for early convulsive status epilepticus is unclear.\nThe analysis addressed five questions involving adults/children with seizures lasting more than 5 minutes:  \n1. Which anticonvulsants are efficacious as initial and subsequent therapy?\n2. What adverse events are associated with anticonvulsant administration?\n3. Which is the most effective benzodiazepine?\n4. Is IV fosphenytoin more effective than IV phenytoin?\n|40-60 min|Attempt IV access and collect electrolytes, hematology, toxicology screen, (if appropriate) anticonvulsant drug levels| | |  \nFIGURE 1. Proposed treatment algorithm for status epilepticus.\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV lorazepam in adults with convulsive status epilepticus without established IV access (level A). Intravenous lorazepam is more effective than IV phenytoin in stopping seizures lasting at least 10 minutes",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of nutritional supplementation in patients with severe alcoholic hepatitis (ASH), particularly due to their poor dietary intake and the need for adequate calorie and protein intake. It suggests that nutritional support, such as enteral nutrition, is beneficial for these patients. Therefore, starting enteral nutrition with a standard formula aligns with the recommendation for nutritional management in this scenario. Options A, B, and D do not directly support the need for immediate nutritional intervention as indicated in the context.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct from fatty liver disease. The recommendations are preceded by statements covering current knowledge of the underlying pathophysiology and pathobiochemistry as well as pertinent methods for the\nReduced oral intake is associated with higher mortality and nutritional supplementation is likely to result in more rapid resolution of HE and elevated serum bilirubin and lower infection risk, and severe ASH is also a hyper-metabolic state. These data support the use of adequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest\npatients with alcohol use disorders and thiamine supplementation is used routinely in clinical practice to prevent Wernicke's encephalopathy and Korsakoff psychosis. There are very limited randomized trials in patients with alcoholic liver disease but none in severe ASH. Since patients with severe ASH have poor dietary intake and micronutrient de\ufb01ciency can affect immune and gut mucosal function, it is reasonable to replace micronutrients. Oral administration of multivitamin and zinc\n1. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol 1985;1(2):141e51.\n2. Achord JL. A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis. Am J Gastroenterol 1987;82(9):871e5.\n16. Schenker S, Halff GA, editors. Nutritional therapy in alcoholic liver disease. Semin Liver Dis; 1993.\n17. Lieber CS. Alcohol, liver, and nutrition. J Am Coll Nutr 1991;10(6):602e32.\n18. Lindor KD, editor. Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis; 1993.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that in patients with acute coronary syndrome (ACS) treated with coronary stent implantation who have tolerated dual antiplatelet therapy (DAPT) without bleeding complications and are not at high bleeding risk, continuation of DAPT for longer than 12 months may be reasonable. Therefore, 12 months is the minimum duration suggested, making option C the correct answer. Options A, B, and D do not align with the provided recommendations for DAPT duration.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable (16,22\u201326,28,30,40,41,43,53,54,72).|\nA new risk score (the \u201cDAPT score\u201d), derived from the Dual Antiplatelet Therapy study, may be useful for decisions about whether to continue (prolong or extend) DAPT in patients treated with coronary stent implantation. Analysis of study data suggests that in patients treated for 1 year with DAPT without significant bleeding or ischemic events, the benefit/risk ratio with prolonged DAPT may be favorable for those with a high DAPT score ($2) because prolonged DAPT reduces net (ischemic plus\n|IIb|ASR|In patients with ACS (NSTE-ACS or STEMI) treated with coronary stent implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 12 months may be reasonable (16,22\u201326,28,30,40,41,43,53,54,72).|\nColors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\nsurgery in patients treated with percutaneous coronary intervention (PCI) and DAPT supersede prior corresponding recommendations in the 6 relevant guidelines. These recommendations for duration of DAPT apply to newer-generation stents and, in general, only to those not treated with oral anticoagulant therapy.",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the treatment of hypothyroidism, indicating that elevated TSH levels with low free T4 levels suggest hypothyroidism. It emphasizes that treatment should be based on individual factors, but does not mention the use of liothyronine (T3) or TSH injections as initial treatments. Levothyroxine (T4) monotherapy is the standard initial treatment for hypothyroidism, making option C the most appropriate choice based on the provided context.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "was first described in cases of central hypothyroidism over 70 years ago (181). Although it rarely occurs, those with adrenal insufficiency, either primary or central, or at risk for it, should be treated with clinically appropriate doses of hydrocortisone until adrenal insufficiency is ruled out (182,183). In the absence of central hypothyroidism, elevated TSH levels may be seen in conjunction with normal T4 clinical hypothyroidism. However, when due to adrenal insufficiency elevated TSH levels\ndue to adrenal insufficiency elevated TSH levels fall with glucocorticoid therapy alone (54,55).\nTreatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases. Grade B, BEL 1\nWhen adrenal insufficiency is present, the diagnosis of subclinical hypothyroidism should be deferred until after glucocorticoid therapy has been instituted because TSH levels may be elevated in the presence of untreated adrenal insufficiency and may normalize with glucocorticoid therapy (54,55) (see L-thyroxine treatment of hypothyroidism).\ninitially made, but even smaller changes may be necessary to achieve goal TSH levels.",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "is_correct": true
  },
  {
    "question": "A 35-year-old pregnant woman, at 20 weeks gestation, presents with a new diagnosis of gonococcal infection. What is the recommended treatment?",
    "options": [
      "Oral azithromycin 1 g single dose",
      "Intramuscular ceftriaxone 500 mg single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Topical erythromycin ointment"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg single dose",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that dual therapy is suggested over single therapy for gonococcal infections, particularly in pregnant women. While specific dosages for dual therapy are not mentioned, ceftriaxone is a commonly recommended treatment for gonococcal infections, especially in pregnant women. The option B states \"Intramuscular ceftriaxone 500 mg single dose,\" which aligns with the context's emphasis on treating gonococcal infections effectively in this population. Other options (A, C, D) do not align with the recommended treatment for gonococcal infections in pregnant women as per the provided context.",
    "reasoning_ground_truth": "The current recommended treatment for gonococcal infection, including in pregnant women, is ceftriaxone 500mg single dose. Doxycycline is contraindicated in pregnancy, azithromycin may not provide adequate coverage, and topical erythromycin is not an adequate treatment for systemic gonococcal infection.",
    "context": "Single therapy (based on recent local resistance data confirming susceptibility to the antimicrobial)  \nRemarks: Treatment failures have been observed after single therapy for gonococcal oropharyngeal infections and therefore dual therapy is suggested over single therapy. This recommendation applies to pregnant women, who should be closely monitored for complications.\nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\n- spectinomycin 25 mg/kg (maximum 75 mg) IM as a single dose.  \nConditional recommendation, very low quality evidence\nInfants of mothers with gonococcal infection can be infected at delivery, resulting in neonatal conjunctivitis manifesting as purulent ocular discharge and swollen eyelids. Untreated conjunctivitis may lead to scarring and blindness.\nConditional  \nIn neonates with gonococcal conjunctivitis, the WHO STI guideline suggests one of the following treatment options:  \n- ceftriaxone 50 mg/kg (maximum 150 mg) IM as a single dose\n- kanamycin 25 mg/kg (maximum 75 mg) IM as a single dose\n- spectinomycin 25 mg/kg (maximum 75 mg) IM as a single dose.\nSince laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated based on local epidemiological patterns.",
    "ground_truth_context": "Six PICO questions were identified for the update on the treatment of genital, anorectal and oropharyngeal gonococcal infections, management of treatment failure, and prevention and treatment of neonatal ophthalmia (see Annex B). These questions pertained to adults and other special populations,  namely adolescents, pregnant women, people living  with HIV, and populations at high risk of acquiring  and transmitting STIs, such as men who have sex with men (MSM) and sex workers.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with rheumatoid arthritis (RA) is currently on methotrexate. The patient's disease activity remains moderate, as indicated by a DAS28 score. What is the next appropriate step in managing RA?",
    "options": [
      "Increase the dose of methotrexate",
      "Add a biologic or targeted synthetic DMARD to methotrexate",
      "Switch to sulfasalazine monotherapy",
      "Prescribe a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic or targeted synthetic DMARD to methotrexate",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that treatment decisions should be reevaluated within a minimum of 3 months based on the efficacy and tolerability of the DMARDs chosen. Since the patient's disease activity remains moderate despite being on methotrexate, the next appropriate step would be to add a biologic or targeted synthetic DMARD to methotrexate, as this aligns with the recommendation to escalate treatment when disease activity is not adequately controlled. Increasing the dose of methotrexate (Option A) is not explicitly supported as the next step in the context provided, and switching to sulfasalazine (Option C) or prescribing oral prednisone (Option D) does not directly address the need for additional disease control in this scenario.",
    "reasoning_ground_truth": "If a patient's RA remains moderately active despite methotrexate therapy, it's recommended to add a biologic or targeted synthetic DMARD. Increasing the dose of methotrexate may be considered in some cases but adding a second DMARD is more appropriate for moderate disease activity.",
    "context": "RA requires early evaluation, diagnosis, and management.Treatment decisions should follow a shared decision-making process.Treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen.Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\n* PICO = population, intervention, comparator, and outcomes; Supp. App. 2 = Supplementary Appendix 2, available on the Arthritis Care & Research website at http://onlinelibrary.wiley.com/doi/10.1002/acr.24596/abstract; DMARD = disease-modifying antirheumatic drug.  \n\u2020 This recommendation refers only to the initial prescribing of methotrexate and is not meant to limit further dose escalation, which often provides additional efficacy.\nTo support high-quality clinical care, the American College of Rheumatology (ACR) regularly updates clinical practice guidelines for the management of rheumatoid arthritis (RA), with the most recent update reported in 2015 (1). The current recommendations address treatment with the following: 1) conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs); 2) glucocorticoids; and 3) use of these medications in\nvoting panel favored a conditional recommendation to initiate methotrexate therapy in this clinical setting because of the vital role of this DMARD in the overall treatment of RA and lack of other comparable therapies without pulmonary risks.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": true
  },
  {
    "question": "A 62-year-old male with a history of primary open-angle glaucoma (POAG) is being treated with prostaglandin eye drops. He mentions having trouble consistently using his medication due to forgetfulness. What is the most appropriate next step?",
    "options": [
      "Switch to a beta-blocker eye drop",
      "Recommend laser trabeculoplasty",
      "Encourage the use of a medication reminder system",
      "Discontinue treatment, since adherence is low"
    ],
    "correct_answer_text": "Encourage the use of a medication reminder system",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context highlights that patient education and the use of reminders can improve adherence to glaucoma treatment. Specifically, it mentions that follow-up telephone calls or smartphone reminders may enhance therapy adherence. Since the patient is experiencing forgetfulness, encouraging the use of a medication reminder system aligns directly with the strategies suggested in the context to improve adherence.",
    "reasoning_ground_truth": "For patients with glaucoma, particularly those with poor adherence, the first step is to implement strategies to improve adherence, including medication reminders, simplify treatment regimens, or encourage caregiver involvement. Switching to a different class of medication or laser trabeculoplasty is not the best initial step and should be considered if adherence remains an issue.",
    "context": "Instilling eye drops correctly is difficult for many patients, and their ability to do so may worsen with aging, comorbidities, and as glaucoma progresses.355, 356 Repeated instruction and counseling about proper techniques for using medication, including waiting at least 5 minutes between multiple drop regimens as well as a clearly written medication regimen and follow-up telephone calls or smartphone reminders, may improve adherence to therapy.353, 357 A Cochrane Systematic Review in 2013\nIf the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be referred for and encouraged to use appropriate vision rehabilitation and social services.703 More information on vision rehabilitation, including materials for patients, is available at\nThe goals of managing patients with POAG are as follows:  \n- Control of IOP in the target range\n- Stable optic nerve/RNFL status\n- Stable visual fields  \nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80, 82, 306-319\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop wastage or inability to properly instill eye drops, before they are permitted to refill their prescription. One study found this was more likely for patients who self-administered eye drop medications\nIf a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the",
    "ground_truth_context": "Ophthalmologists should strive to provide education that is clear, relevant, and accessible to the patient and their caregiver(s).",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male is admitted to the hospital with an acute illness. He has a high risk of venous thromboembolism (VTE) based on the Padua risk score. What is the recommended approach for VTE prophylaxis?",
    "options": [
      "No prophylaxis, just early ambulation",
      "Mechanical prophylaxis with compression stockings",
      "Pharmacological prophylaxis with parenteral anticoagulation",
      "Combined pharmacological and mechanical prophylaxis"
    ],
    "correct_answer_text": "Pharmacological prophylaxis with parenteral anticoagulation",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that strong recommendations include the provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at acceptable bleeding risk. Since the patient is admitted with an acute illness and has a high risk of VTE (Padua score \u2265 4), pharmacological prophylaxis with parenteral anticoagulation is the appropriate approach, as indicated by the guidelines.",
    "reasoning_ground_truth": "The guidelines recommend using parenteral anticoagulation for VTE prophylaxis in acutely ill patients at high risk. Mechanical prophylaxis may be considered when anticoagulation is contraindicated or as an adjunct therapy, but not as the first line strategy.",
    "context": "*A total of 60.3% of patients in this study were low risk (Padua score 0-3). VTE prophylaxis was administered by provider choice from among several medications and with or without concomitant compression stockings.  \nVTE incidence without VTE prophylaxis:  \n- Padua score 0 to 3: 0.3%\n- Padua score $ 4: 11%  \nAmong at-risk patients (Padua score $ 4):  \n- Overall VTE hazard ratio (HR), 32 (95% CI, 4.1-251)\n- Incidence of VTE\n- - No prophylaxis: 11%\n- With prophylaxis: 2.2%\nStrong recommendations included provision of pharmacological VTE prophylaxis in acutely or critically ill inpatients at acceptable bleeding risk, use of mechanical prophylaxis when bleeding risk is unacceptable, against the use of direct oral anticoagulants during hospitalization, and against extending pharmacological prophylaxis after hospital discharge. Conditional recommendations included not to use VTE prophylaxis routinely in long-term care patients or outpatients with minor VTE risk\nAll guidelines advocated assessing the risk of VTE and bleeding in admitted medical patients. The American College of Physicians issued 2 additional recommendations: for the use of heparin or a related drug, unless patients were at high bleeding risk, and against use of graduated compression stockings. The ACCP guidelines were most similar to the ASH guideline in scope and methods. The ACCP advised not to use prophylaxis in medical patients at low risk of VTE, based on the Padua Prediction\nBased on enhanced understanding of these issues, a paradigm shift in VTE risk assessment and prevention is underway that prompts clinicians to strive for individualized prophylaxis based on VTE and bleeding risk. Over the last decade, several quantitative VTE risk-assessment models (RAMs) were developed for medical inpatients. The 2 most extensively studied are the empirically derived Padua score and the database-derived IMPROVE score (Table 1). Both have been externally validated and showed\nprophylaxis for persons without risk factors. For long-distance travelers at increased risk for VTE, the ACCP recommended 15- to 30-mm Hg below-knee graduated compression stockings, frequent ambulation, calf muscle exercise, or sitting in an aisle seat. They recommended against the use of aspirin or anticoagulants. The ASH panel recommended LMWH or graduated compression stockings and the use of aspirin if these were not feasible or available.",
    "ground_truth_context": "We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89 (H. Vissinger and S. Husted, unpublished data, 1995) in these reviews evaluating outcomes relevant to this question.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old male with a history of chronic kidney disease (CKD) is being evaluated for kidney function. His eGFR based on creatinine is 40 mL/min/1.73m^2. What additional test should be considered?",
    "options": [
      "Repeat creatinine-based eGFR in 3 months",
      "Measure cystatin C to estimate eGFR",
      "Perform a kidney biopsy",
      "Start renal replacement therapy"
    ],
    "correct_answer_text": "Measure cystatin C to estimate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context recommends using creatinine-based estimated glomerular filtration rate (eGFRcr) as the first method to evaluate GFR in adults at risk for CKD. It also states that if cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (eGFRcr-cys) for greater accuracy. Since the patient has a history of CKD and an eGFR of 40 mL/min/1.73m^2, measuring cystatin C to estimate eGFR would be a logical next step to improve the accuracy of the assessment.",
    "reasoning_ground_truth": "The initial test for evaluating GFR is eGFRcr. If eGFRcr is suspected to be inaccurate, then cystatin C should be measured and eGFRcr-cys should be estimated. A kidney biopsy would be indicated if the cause of CKD is uncertain, not for the evaluation of GFR. Renal replacement therapy is not indicated unless the eGFR is much lower.",
    "context": "Recommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]).\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]) (1B).\nThe KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommended \u201cto report eGFRcr in adults using the 2009 CKD-EPI creatinine equation. An alternative creatinine-based GFR estimating equation is acceptable if it has been shown to improve accuracy of GFR estimates compared to the 2009 CKD-EPI creatinine equation.\u201d We are updating this recommendation to accommodate the availability of alternative equations that also have high levels of accuracy.\nWhat is the diagnostic accuracy of eGFR based on measurements of cystatin C, creatinine, or their combination compared with mGFR among people with and without CKD?\nIn this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers. In contrast to the previous",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "is_correct": true
  },
  {
    "question": "A 42-year-old female with a history of migraine presents with frequent, severe headaches. She has tried several abortive therapies with limited success. What is the next step in her management?",
    "options": [
      "Initiate a preventative migraine therapy",
      "Refer her for neurosurgery",
      "Prescribe a higher dose of her current abortive medication",
      "Recommend lifestyle modifications only"
    ],
    "correct_answer_text": "Initiate a preventative migraine therapy",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that approximately 38% of migraineurs need preventive therapy, and the article's objective is to provide updated evidence-based recommendations for the preventive treatment of migraine headache. Given that the patient has a history of migraine and has tried several abortive therapies with limited success, initiating a preventative migraine therapy (Option A) is the logical next step in her management, as it aligns with the need for preventive strategies highlighted in the context. The other options do not directly address the need for preventive treatment based on the patient's situation.",
    "reasoning_ground_truth": "For patients with frequent, severe migraines or if abortive therapies are not effective, preventative therapy should be considered. Other options are not appropriate at this stage.",
    "context": "It seems reasonable that a clinician be mindful of comorbid and coexistent conditions in patients with migraine, to maximize potential treatment efficacy and minimize AE risk. Table e-2 identifies which therapies to consider or avoid when common migraine coexisting conditions are present. Because migraine is frequent in women of childbearing age, the potential for adverse fetal effects related to migraine prevention strategies is particularly concerning.\nThis article addresses the safety and efficacy of pharmacologic therapies for migraine prevention. Separate guidelines are available for botulinum toxin. The 2008 guideline included a Level B recommendation that botulinum toxin was probably ineffective for treatment of episodic migraine. A new guideline is in development. An updated guideline on nonsteroidal anti-inflammatory drugs and complementary alternative treatments has been approved for publication as a companion to this guideline.\nObjective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: What pharmacologic therapies are proven effective for migraine prevention?  \nMethods: The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications available in the United States for migraine prevention.\nThe following medication is established as ineffective and should not be offered for migraine prevention:  \n- Lamotrigine\nEpidemiologic studies suggest approximately 38% of migraineurs need preventive therapy, but only 3%\u201313% currently use it. In 2000, the American Academy of Neurology (AAN) published guidelines for migraine prevention. Since then, new clinical studies have been published on the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which pharmacologic therapies are proven",
    "ground_truth_context": "Evidence to support pharmacologic treatment strategies for migraine prevention indicates which treatments might be effective but is insufficient to establish how to choose an optimal therapy.",
    "is_correct": true
  },
  {
    "question": "A 30-year-old male presents with a 3-day history of nasal congestion, facial pain, and purulent nasal discharge. He reports no improvement after using over-the-counter decongestants. What is the most appropriate initial management strategy?",
    "options": [
      "Start antibiotic therapy immediately",
      "Prescribe nasal corticosteroids",
      "Recommend watchful waiting for 7 days",
      "Order a sinus CT scan"
    ],
    "correct_answer_text": "Recommend watchful waiting for 7 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context suggests that for a patient with nasal congestion, facial pain, and purulent discharge who has not improved with over-the-counter decongestants, the most appropriate initial management strategy is watchful waiting for 7 days. There is no indication in the context that immediate antibiotic therapy is warranted without further assessment, and while nasal corticosteroids may provide some benefit, they are not the first-line recommendation in this scenario. A sinus CT scan is also not indicated as an initial management step. Therefore, option C aligns best with the context provided.",
    "reasoning_ground_truth": "The guideline recommends watchful waiting as an initial management strategy for uncomplicated acute bacterial rhinosinusitis, regardless of severity. Antibiotics should not be used right away unless symptoms fail to improve. A CT scan is not required at this stage.",
    "context": "Oral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are\nhave been used to treat nasal congestion associated with the common cold for many years.103-107 There are no RCTs that specifically study the efficacy of decongestants for ABRS, but 2 small studies have shown that xylometazoline nasal spray reduces congestion of sinus and nasal mucosa on imaging studies65,108 and is superior to a single orally administered dose of pseudoephedrine.108 Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics\n2. Saline irrigations, or washing out the nose with salt water, can relieve symptoms and remove mucus that is hard to blow out.\n3. Nasal steroid sprays can reduce symptoms after 15 days of use, but the benefit is small (about 14 people must use them to get 1 person better), and side effects include headache, nasal itching, and nosebleeds.\nDecongestants may help you breathe easier and can be taken as a nasal spray (for no more than 3 days in a row to avoid worsening congestion) or by mouth.|\nxylometazoline spray was added to antibiotics for ABRS.97 Topical decongestants should not be used more than 3 to 5 consecutive days without a prolonged intervening drug-free period due to their propensity to cause rebound congestion and rhinitis medicamentosa.87\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the use of nasal saline in both physiologic and hypertonic concentrations.",
    "ground_truth_context": "Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhi-nosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline).",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a long history of sun exposure presents with several rough, scaly lesions on his scalp and face. He is diagnosed with actinic keratoses (AKs). What is the recommended initial treatment?",
    "options": [
      "Surgical excision of the lesions",
      "Cryotherapy of the lesions",
      "Topical application of a medication approved for AKs",
      "Observation only"
    ],
    "correct_answer_text": "Topical application of a medication approved for AKs",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients with actinic keratoses (AKs), the recommended treatments include field treatment with topical agents such as 5-fluorouracil and imiquimod. This indicates that the initial treatment for AKs is the topical application of a medication approved for AKs, making option C the correct choice. Options A, B, and D are not mentioned as recommended initial treatments in the provided context.",
    "reasoning_ground_truth": "The clinical question asks if topically applied agents should be used for the treatment of AKs. Topical therapy is a standard first line treatment option for AK's.",
    "context": "Actinic keratosis (AK) is one of the most common conditions diagnosed and treated by dermatologists in the United States (US). These guidelines address the management of AK from the perspective of US dermatologists, other practitioners who treat AK, and patients. Premalignant neoplasia on nonkeratinizing epithelium, such as actinic cheilitis, is not addressed.\n|No.|Recommendation|\n|---|---|\n|UV protection| |\n|1.0|For patients with AK, we recommend the use of UV protection Remarks: UV protection may include sun avoidance, sun-protective clothing, and broad-spectrum sunscreen|\n|Topical agents| |\n|2.1|For patients with AKs, we recommend field treatment with 5-fluorouracil|\n|2.2|For patients with AKs, we recommend field treatment with imiquimod|\nActinic keratoses are keratinocyte neoplasms occurring on skin that has had long-term exposure to ultraviolet radiation.\nAK, Actinic keratosis; US, United States.\nThe use of topically applied creams, gels, and solutions for the management of AK is common in dermatology practice. Topical agents can be used focally or in broad areas and are particularly advantageous when AKs occur in areas of high density or areas with indistinct clinical borders. The recommended topical agents all have the potential for generating local skin reactions. As skin reactions can result in the termination of treatment without reaching the desired therapeutic outcome, the",
    "ground_truth_context": "Clinical question (CQ) 1 asks: Should topically applied agents be used for the treatment of AKs?.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old patient with chronic kidney disease (CKD) and type 2 diabetes is starting on a new antihypertensive medication. What is the most important information to consider regarding drug dosing?",
    "options": [
      "Whether the medication is metabolized by the liver",
      "Whether the medication requires a loading dose",
      "The patient's estimated glomerular filtration rate (eGFR)",
      "The patient's blood pressure reading at the time of medication initiation"
    ],
    "correct_answer_text": "The patient's estimated glomerular filtration rate (eGFR)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of assessing medication appropriateness for people with CKD, particularly due to their susceptibility to polypharmacy and the need for careful consideration of drug dosing. It specifically mentions that patients with CKD should inform prescribers about their condition to facilitate consideration of doses and potential side effects. The estimated glomerular filtration rate (eGFR) is a critical factor in determining appropriate medication dosing for patients with kidney disease, making option C the most relevant and important information to consider.",
    "reasoning_ground_truth": "The eGFR is important for guiding decisions related to the choice and dosing of medications in patients with CKD, particularly those medications that are renally cleared.",
    "context": "People with CKD are particularly susceptible to polypharmacy due to multiplicity of comorbidities and multiple physician or health system encounters related to those. Most people with CKD not treated with dialysis receive 6\u201312 different medications per day. Polypharmacy leads to increased pill burden and potential harm due to medication errors and drug-drug interactions. Thus, healthcare providers, including clinical pharmacists, should be diligent in assessing medication appropriateness,\nWe recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in people with CKD, with or without diabetes (1B).  \nS158 Kidney International (2024) 105 (Suppl 4S), S117\u2013S314\nWe recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) for people with CKD and severely increased albuminuria (G1\u2013G4, A3) without diabetes (1B).\nWe recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) for people with CKD and severely increased albuminuria (G1\u2013G4, A3) without diabetes (1B).\nPeople with kidney disease have a role in drug stewardship, and given that they may receive medications from non-nephrology healthcare providers, people with CKD should be encouraged to inform those prescribers that they have kidney disease to facilitate consideration of doses and potential side effects of medications. Thus, education and information for people with CKD inclusive for their population (i.e., literacy level and languages) are encouraged. Although brochures and conversations may",
    "ground_truth_context": "An assessment of GFR is important for guiding decisions related to the choice and dosing of medications. Section 1.2 addresses the accuracy of validated eGFR equations, as well as indications for the use of eGFRcr-cys or mGFR.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old woman with a recent diagnosis of community acquired pneumonia (CAP) is being discharged from the hospital. She has multiple comorbidities. Which of the following is the most appropriate antibiotic regimen for outpatient therapy?",
    "options": [
      "Amoxicillin monotherapy",
      "Azithromycin monotherapy",
      "A fluoroquinolone",
      "Doxycycline monotherapy"
    ],
    "correct_answer_text": "A fluoroquinolone",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for patients without comorbidities, amoxicillin or doxycycline is recommended for outpatient treatment of CAP. However, it does not provide recommendations for patients with multiple comorbidities. Given that the patient in the question has multiple comorbidities, the most appropriate antibiotic regimen for outpatient therapy would typically involve a fluoroquinolone, which is often used for patients with more complex cases or comorbidities. Therefore, option C is the most suitable choice based on the context provided.",
    "reasoning_ground_truth": "For outpatients with comorbidities, a respiratory fluoroquinolone or a combination of a beta-lactam and a macrolide is appropriate. Monotherapy with amoxicillin, azithromycin or doxycycline are options for patients without comorbidities and may not provide adequate coverage for all CAP pathogens in a patient with comorbidities.",
    "context": "In the Outpatient Setting, Which Antibiotics Are Recommended for Empiric Treatment of CAP in Adults?\nFor patients without comorbidities that increase the risk for poor outcomes, the panel recommended amoxicillin 1 g every 8 hours or doxycycline 100 mg twice daily. The recommendation for amoxicillin was based on several studies that showed ef\ufb01cacy of this regimen for inpatient CAP despite presumed lack of coverage of this antibiotic for atypical organisms. This treatment also has a long track record of safety. The recommendation for doxycycline was based on limited clinical trial data, but a\nIn the Inpatient Setting, Which Antibiotic Regimens Are Recommended for Empiric Treatment of CAP in Adults without Risk Factors for MRSA and P. aeruginosa?\nWe identified 16 relevant RCTs comparing two antibiotic regimens for the treatment of outpatient CAP (69\u201384). Meta-analyses of each of these groups of studies revealed no differences in relevant outcomes between any of the compared regimens. Similar findings have been noted.  \nreported in a 2008 meta-analysis of antibiotic treatment for outpatient CAP (85).\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?",
    "ground_truth_context": "the panel believed that fluoroquinolone therapy was justified for adults with comorbidities and CAP managed in the outpatient setting.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old man with a history of heart failure is hospitalized for an acute exacerbation. He develops acute kidney injury. What is the most appropriate initial test for evaluating GFR in this patient?",
    "options": [
      "Measured GFR using exogenous filtration markers",
      "eGFR based on serum cystatin C (eGFRcys)",
      "eGFR based on serum creatinine (eGFRcr)",
      "A renal ultrasound"
    ],
    "correct_answer_text": "eGFR based on serum creatinine (eGFRcr)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that the initial test for the evaluation of GFR should be creatinine-based estimated GFR (eGFRcr), which is routinely available for most people. Since the patient is hospitalized and requires an initial evaluation of GFR, eGFRcr is the most appropriate choice according to the provided guidelines.",
    "reasoning_ground_truth": "The initial test for evaluation of GFR is eGFRcr. Cystatin C is a supportive test to be used if eGFRcr is suspected of being inaccurate. mGFR is only needed when eGFR is not accurate enough for clinical decision making. A renal ultrasound may be indicated if the cause of AKI is uncertain, but not for GFR evaluation.",
    "context": "accurate assessment of GFR is needed for clinical decision-making, then, if available, GFR should be measured using plasma or urinary clearance of exogenous filtration markers. *Initial test may be estimated GFR by cystatin C (eGFRcys or eGFRcr-cys) in otherwise healthy populations with changes in creatinine generation due to non-GFR determinants such as changes in muscle mass or creatinine secretion or extrarenal elimination due to the use of specific medications. \u2020Sources of error in\naccurate assessment of GFR is needed for clinical decision-making, then, if available, GFR should be measured using plasma or urinary clearance of exogenous filtration markers. *Initial test may be estimated GFR by cystatin C (eGFRcys or eGFRcr-cys) in otherwise healthy populations with changes in creatinine generation due to non-GFR determinants such as changes in muscle mass or creatinine secretion or extrarenal elimination due to the use of specific medications. \u2020Sources of error in\nApproach to glomerular filtration rate (GFR) evaluation using initial and supportive tests. The algorithm describes the approach to the evaluation of GFR. The approach uses initial and supportive testing to develop a final assessment of true GFR and to apply it in individual decision-making. The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic metabolic panel.\nFigure 11 | Approach to glomerular filtration rate (GFR) evaluation using initial and supportive tests. The algorithm describes the approach to the evaluation of GFR. The approach uses initial and supportive testing to develop a final assessment of true GFR and to apply it in individual decision-making. The initial test for the evaluation of GFR is creatinine-based estimated GFR (eGFRcr), which will be available for most people because creatinine is measured routinely as part of the basic\nIn this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers. In contrast to the previous",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease,1 the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with a recent diagnosis of CKD is being educated about her condition. What is the most important aspect to address in her education?",
    "options": [
      "Detailed kidney anatomy",
      "The type of kidney failure and its treatment options",
      "Specific dietary restrictions",
      "The etiology of CKD, its management, and the available kidney failure management options"
    ],
    "correct_answer_text": "The etiology of CKD, its management, and the available kidney failure management options",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context emphasizes the importance of educating people with CKD about their condition, specifically mentioning the need to address the etiology of CKD, its management, and available kidney failure management options as critical components of patient education. This aligns with the need for comprehensive understanding for effective self-care management, making option D the most relevant choice.",
    "reasoning_ground_truth": "Educational topics should cover knowledge about CKD, including the etiology, signs, and symptoms, treatment to slow progression, treatment of complications, and available kidney failure management options. Focusing on the etiology of CKD, its management, and the available kidney failure management options is essential for patient self-management.",
    "context": "People with kidney disease have a role in drug stewardship, and given that they may receive medications from non-nephrology healthcare providers, people with CKD should be encouraged to inform those prescribers that they have kidney disease to facilitate consideration of doses and potential side effects of medications. Thus, education and information for people with CKD inclusive for their population (i.e., literacy level and languages) are encouraged. Although brochures and conversations may\nEducate and inform people with CKD regarding the expected benefits and possible risks of medications so that they can identify and report adverse events that can be managed.\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.\nUse renal dietitians or accredited nutrition providers to educate people with CKD about dietary adaptations regarding sodium, phosphorus, potassium, and protein intake, tailored to their individual needs, and severity of CKD and other comorbid conditions.\nEducation programs that also involve care partners where indicated are important to promote informed, activated people with CKD.  \nAn effective patient education program is a critical success factor of self-care management support strategies. Education should address 3 main issues:  \n1. standardized educational topics and resources,\n2. strategy to provide education effectively, and\n3. patient-centered concept.",
    "ground_truth_context": "Standardized educational topics should cover 3 main subject areas: knowledge about CKD, knowledge about treatment to slow progression and complications of CKD, and knowledge about the kidney failure management options.",
    "is_correct": true
  },
  {
    "question": "A 35-year-old male presents with a 2-day history of fever, cough, and shortness of breath. He is diagnosed with community-acquired pneumonia (CAP). He is admitted to the hospital.  What is the recommended approach to determine if he needs a higher level of care (ICU admission)?",
    "options": [
      "Use a clinical prediction tool plus clinical judgment.",
      "Rely solely on clinical judgment.",
      "Use a serum procalcitonin test to assess disease severity",
      "Obtain blood cultures and wait for results before deciding on level of care."
    ],
    "correct_answer_text": "Use a clinical prediction tool plus clinical judgment.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that clinicians should use a validated clinical prediction rule for prognosis, specifically recommending the Pneumonia Severity Index (PSI) in conjunction with clinical judgment to determine the need for hospitalization in adults diagnosed with CAP. This supports option A, which combines a clinical prediction tool with clinical judgment, as the appropriate approach for assessing the need for ICU admission. Options B, C, and D do not align with the recommended approach outlined in the context.",
    "reasoning_ground_truth": "For determining inpatient care, the guidelines recommends using a clinical severity tool like the IDSA/ATS minor criteria combined with clinical judgment to assess the need for higher intensity of treatment such as ICU admission. Other options do not use the best evidence based approach.",
    "context": "The 2007 IDSA/ATS CAP guidelines recommended a set of two major and nine minor criteria to define severe pneumonia requiring ICU admission (Table 1). These criteria were based on empirical evidence from published studies and expert consensus. All elements are routinely available in emergency department settings and are electronically calculable (51, 61). Several groups have validated these criteria in pneumonia cohorts from different countries (57\u201359, 61), with a meta-analysis reporting one\nIn addition to clinical judgement, we recommend that clinicians use a validated clinical prediction rule for prognosis, preferentially the Pneumonia Severity Index (PSI) (strong recommendation, moderate quality of evidence) over the CURB-65 (tool based on confusion, urea level, respiratory rate, blood pressure, and age &gt;=65) (conditional recommendation, low quality of evidence), to determine the need for hospitalization in adults diagnosed with CAP.\nRecommendation. We recommend that standard antibacterial treatment be initially prescribed for adults with clinical and radiographic evidence of CAP who test positive for influenza in the inpatient and outpatient settings (strong recommendation, low quality of evidence).\nGiven the expansion in information related to the diagnostic, therapeutic, and management decisions for the care of patients with CAP, we have purposely narrowed the scope of this guideline to address decisions from the time of clinical diagnosis of pneumonia (i.e., signs and symptoms of pneumonia with radiographic confirmation) to completion of antimicrobial therapy and follow-up chest imaging.\nIn inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):  \n- A b-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or\n- A b-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).",
    "ground_truth_context": "We recommend the 2007 IDSA/ATS severe CAP criteria over other published scores, because they are composed of readily available severity parameters and are more accurate than the other scores described above.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old patient with CKD is being evaluated for the cause of his condition. After initial evaluation, a kidney biopsy is being considered. When is it most appropriate to perform a kidney biopsy?",
    "options": [
      "When the eGFR is below 30 mL/min/1.73 m\u00b2.",
      "When it is thought that it can provide information for cause and treatment.",
      "If the CKD is suspected to be caused by diabetes.",
      "Only after all other tests have been exhausted."
    ],
    "correct_answer_text": "When it is thought that it can provide information for cause and treatment.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes that a kidney biopsy is suggested as an acceptable and safe diagnostic test to evaluate the cause of CKD and guide treatment decisions when clinically appropriate. This indicates that the most appropriate time to perform a kidney biopsy is when it is believed to provide valuable information regarding the cause and treatment of the patient's condition, aligning directly with option B. The other options do not reflect the specific criteria for performing a kidney biopsy as outlined in the context.",
    "reasoning_ground_truth": "Kidney biopsy should be considered when it can provide information to identify the cause, facilitate prognostication and treatment strategies.. The eGFR value does not dictate the need for a biopsy. Other options are not the correct reason for performing a biopsy.",
    "context": "Values and preferences. The Work Group judged that many people with CKD would choose to undergo a kidney biopsy to establish the cause of their CKD more accurately and potentially offer prognostic information. Thus, this recommendation puts a high value on the specificity of a kidney biopsy for the evaluation of cause as well as the very low certainty evidence demonstrating a low risk of complications associated with kidney biopsy. Because the potential that the information gleaned from the\n- Ultrasound\n- Urinalysis and urine sediment\n- Urine albumin-to-creatinine ratio\n- Serologic tests\n- Kidney biopsy\n- Genetic testing  \nRecommendation 1.1.4.1: We suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate (2D).  \nThis recommendation places a high value on an acceptable safety profile of kidney biopsies when used to evaluate the cause of CKD and to plan appropriate treatment.\nWe suggest performing a kidney biopsy as an acceptable, safe, diagnostic test to evaluate cause and guide treatment decisions when clinically appropriate.\nWhat is the diagnostic and prognostic bene\ufb01t and safety of kidney biopsy among people with CKD?\nwould be confirmed to have CKD. In both cases, repeat ascertainment of GFR and kidney damage is recommended for accurate diagnosis and staging. The timing of the evaluation depends on clinical judgment, with earlier evaluation for those suspected of having AKI and later evaluation for those suspected of having CKD.",
    "ground_truth_context": "Kidney biopsy is an important part of the investigations for the cause of CKD. It is often deferred because of the potential for harm or lack of recognition of potential utility. The evi-dence to support safety of biopsy is heterogeneous and therefore uncertain, but in the studies evaluated, appears to confer low risk of harm, supporting our suggestion that kidney biopsies should be considered when it is thought that they can provide information to identify cause, facilitate prognostication, and inform treatment strategies.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with a history of atrial fibrillation and CKD is being started on anticoagulation. What is the most appropriate approach for selecting the medication?",
    "options": [
      "Start warfarin and monitor INR closely.",
      "Use a non-vitamin K antagonist oral anticoagulant (NOAC) without regard to kidney function.",
      "Use a NOAC, but monitor for bleeding risks.",
      "Avoid anticoagulation due to the risk of bleeding."
    ],
    "correct_answer_text": "Use a NOAC, but monitor for bleeding risks.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context recommends the use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation for people with CKD G1\u2013G4. While it does not explicitly state to monitor for bleeding risks, it does mention the importance of treating modifiable risk factors for bleeding and using gastroprophylaxis, indicating that monitoring for bleeding risks is prudent when using anticoagulants in this population. Therefore, option C aligns with the context's guidance on using NOACs while being cautious about bleeding risks.",
    "reasoning_ground_truth": "The guideline addresses the use of NOACs in CKD with atrial fibrillation, and recommends their use while being mindful of bleeding risks. Warfarin is not recommended due to challenges with monitoring and efficacy. Anticoagulation is not contraindicated, and a careful assessment of benefit and harm should be made. NOAC use in CKD requires assessment of dose and kidney function.",
    "context": "We recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial fibrillation in people with CKD G1\u2013G4 (1C).\nWe recommend use of non\u2013vitamin K antagonist oral anticoagulants (NOACs) in preference to vitamin K antagonists (e.g., warfarin) for thromboprophylaxis in atrial \ufb01brillation in people with CKD G1\u2013G4 (1C).\ntherapy. Oral anticoagulants should be considered for stroke prevention with a CHA DS 2 -VASc score of 1 in men or 2 in women, considering net clinical benefit and values and preferences of people with CKD. Oral anticoagulants are clearly recommended for stroke prevention in people with atrial fibrillation and a CHA 2DS -VASc score \u22652 in men or \u22653 in women. Our Work Group considered that oral anticoagulation for thromboprophylaxis should nearly always be considered for preventing stroke in\nConsiderations for implementation. A decision not to anticoagulate for thromboembolic prophylaxis due to low risk would ideally be re-evaluated at each consultation and at least every 6 months. When using antithrombotic therapy in people with CKD, it is prudent to treat modifiable risk factors for bleeding (e.g., alcohol intake) and use gastroprophylaxis with a PPI, particularly when combined with antiplatelet therapy.\nand management. It is beyond the scope of this KDIGO guideline to consider all aspects of the diagnosis and management of atrial fibrillation in people with CKD. The ERT review focused on the role of non\u2013vitamin K antagonist oral anticoagulants (NOACs) versus warfarin for thromboprophylaxis in CKD.",
    "ground_truth_context": "Figure S12. PRISMA diagram for the clinical question \u201cWhat are the effects of NOACs with or without warfarin compared to placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?\u201d",
    "is_correct": true
  },
  {
    "question": "A 75 year old male is admitted to the hospital with decompensated heart failure. He is treated with IV furosemide but remains volume overloaded. What type of fluid should be used for volume resuscitation in this case?",
    "options": [
      "0.9% Normal Saline",
      "5% Dextrose in water",
      "Albumin",
      "Lactated Ringers Solution"
    ],
    "correct_answer_text": "Albumin",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that \"initially normal saline may be effective\" for volume resuscitation, particularly in patients who are volume depleted. Given that the patient is experiencing decompensated heart failure and remains volume overloaded despite diuretic treatment, the recommendation aligns with using normal saline for volume resuscitation. Other options do not have explicit support in the context for this specific scenario.",
    "reasoning_ground_truth": "While saline can be used for volume resuscitation, in patients with severe hypoalbuminemia from liver failure or heart failure, albumin can be used as a drug for volume resuscitation. Although this patient does not have liver failure, his use case is similar.",
    "context": "of any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided by biochemical parameters and clinical status; initially normal saline may be effective. Hyperchloraemia should be avoided, as it has been associated with increased risk of renal failure and other morbidities with Ringers lactate (recognising the risk of hypotonicity) or a balanced solution as required. Balanced solutions are buffered with either bicarbonate or\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\n- Persistent hypotension requires critical care management, with application of vasopressive agents guided by appropriate monitoring techniques (evidence level II-3, grade of recommendation 1).\n- Norepinephrine is the vasopressor of choice (evidence level III, grade of recommendation 1).\nIn the cohort of patients with ascites due to subacute liver failure or acute Budd-Chiari syndrome, elevated intra-abdominal pressure may be present. This may alter response to volume loading, in addition to increasing risk of gut dysfunction and AKI, response to fluid resuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index\nIn addition to hyperlactataemia, if clinical examination at initial presentation reveals no evidence of cardiorespiratory disease (e.g., jugular venous pressure not elevated), and the patient has evidence of end organ dysfunction (peripheral hypoperfusion, acidosis, oliguria or renal failure), then it is highly likely that they are volume depleted and will respond to an appropriate fluid challenge. There is little evidence supporting the use of any specific fluid for volume loading in ALF.\nAlthough their use has been documented in the literature, diuretics have no role in HAPE treatment, particularly because many HAPE patients have concurrent intravascular volume depletion. Recommendation Grade: 2C.",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "is_correct": false
  },
  {
    "question": "A 50 year old male is admitted for a planned coronary artery bypass graft (CABG) surgery. He is currently on dual antiplatelet therapy (DAPT).  What is the recommendation for continuation of DAPT?",
    "options": [
      "DAPT should be stopped at least 5 days prior to surgery.",
      "DAPT should be continued through the surgery",
      "DAPT should be stopped 7 days prior to surgery",
      "DAPT should be continued up to 3 days prior to surgery"
    ],
    "correct_answer_text": "DAPT should be stopped at least 5 days prior to surgery.",
    "correct_answer_idx": 0.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that in patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed. This implies that DAPT should be continued through the surgery, supporting option B directly.",
    "reasoning_ground_truth": "While the guidelines focus on duration of DAPT, the general consensus for elective surgeries including CABG is to stop DAPT at least 5 days prior to surgery, with some exceptions made for very high risk patients.",
    "context": "The scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention\u201d (9), \u201c2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery\u201d (10), \u201c2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients\nSee Online Data Supplements 4, 6, 10, and 11 for evidence supporting these recommendations.  \n|Recommendations for Duration of DAPT in Patients Undergoing CABG|COR|LOE|RECOMMENDATIONS|\n|---|---|---|---|\n|In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y12 inhibitor therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is completed.|I|C-EO| |\nColors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as possible after surgery.|",
    "ground_truth_context": "Issues and recommendations with regard to P2Y12 inhibitor \u201cpre-treatment,\u201d \u201cpreloading,\u201d and loading are beyond the scope of this document but are addressed in other guidelines.",
    "is_correct": false
  },
  {
    "question": "A 60-year-old male with a history of hypertension presents with a persistent cough, fever, and shortness of breath. A chest X-ray reveals a right lower lobe infiltrate. Initial blood cultures are negative. What is the most appropriate next step in his management?",
    "options": [
      "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
      "Prescribe cough suppressants and monitor symptoms",
      "Perform a bronchoscopy to obtain lower respiratory secretions for culture",
      "Order a CT scan of the chest with contrast to rule out pulmonary embolism"
    ],
    "correct_answer_text": "Start empiric antibiotic therapy for community-acquired pneumonia (CAP)",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that longer courses of antibiotic therapy are recommended for pneumonia, particularly in cases of community-acquired pneumonia (CAP). Given the patient's symptoms of persistent cough, fever, and shortness of breath, along with the chest X-ray revealing a right lower lobe infiltrate, starting empiric antibiotic therapy for CAP is the most appropriate next step in management. The context also suggests that blood cultures should not routinely be obtained in adults with CAP, which aligns with the patient's initial negative blood cultures. Therefore, option A is directly supported by the context.",
    "reasoning_ground_truth": "The patient's symptoms and chest X-ray findings are consistent with CAP. The guidelines recommend initiating **empiric antibiotic therapy** for possible bacterial infection or coinfection. Although blood cultures are recommended, they should not delay the start of antibiotic treatment. The other options are not the first-line steps for a typical CAP case.",
    "context": "Longer courses of antibiotic therapy are recommended for 1) pneumonia e59  \ncomplicated by meningitis, endocarditis, and other deep-seated infection; or 2) infection with other, less-common pathogens not covered in these guidelines (e.g., Burkholderia pseudomallei, Mycobacterium tuberculosis or endemic fungi).\nBefore initiating treatment, care should be taken to rule out other causes of respiratory symptoms at high altitude, such as pneumonia, viral upper respiratory tract infection, mucus plugging, bronchospasm, or myocardial infarction. Descent is the first treatment priority in persons with HAPE. If descent cannot be initiated as a result of logistical factors, supplemental oxygen or a portable hyperbaric chamber should be used. Patients who have access to oxygen (eg, a hospital or high altitude\nGiven the variability of NTM lung disease severity and response to treatment, patients should be closely comanaged with an infectious disease or pulmonary specialist.\nWe recommend not obtaining blood cultures in adults with CAP managed in the outpatient setting (strong recommendation, very low quality of evidence).  \nWe suggest not routinely obtaining blood cultures in adults with CAP managed in the hospital setting (conditional recommendation, very low quality of evidence).\n(>10%) of invasive PNS S pneumoniae*, those with severe infection (eg, evidence of systemic toxicity with temperature of 39\u00b0C [102\u00b0F] or higher, and threat of suppurative complications), age >65 years, recent hospitalization, antibiotic use within the past month, or those who are immunocompromised.125",
    "ground_truth_context": "our recommendations are to initially treat empirically for possible bacterial infection or coinfection. Routinely obtaining blood cultures may generate false-positive results that lead to unnecessary antibiotic use and increased length of stay.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old female with known chronic kidney disease (CKD) and type 2 diabetes is admitted for a urinary tract infection. Her estimated glomerular filtration rate (eGFR) based on serum creatinine (SCr) is 35 mL/min/1.73 m\u00b2. What is the most appropriate approach for medication dosing?",
    "options": [
      "Use eGFR based solely on serum creatinine for drug dosing.",
      "Use equations that combine both creatinine and cystatin C for drug dosing.",
      "Immediately initiate dialysis",
      "Discontinue all medications until the patient's kidney function improves."
    ],
    "correct_answer_text": "Use equations that combine both creatinine and cystatin C for drug dosing.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that for most people and clinical settings, validated eGFR equations using serum creatinine (SCr) are appropriate for drug dosing (Practice Point 4.2.2). Since the patient's eGFR is based on SCr and falls within the recommended guidelines for dosing medications in patients with CKD, option A is the most appropriate approach. Options B, C, and D are not supported by the context provided.",
    "reasoning_ground_truth": "For most people, validated eGFR equations using SCr are appropriate for drug dosing. However, when **more accuracy** is needed, such as with a narrow therapeutic range, drug toxicity, or when eGFR estimates may be unreliable, equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "context": "Practice Point 4.2.1: Consider GFR when dosing medications cleared by the kidneys.  \nPractice Point 4.2.2: For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing.\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]).\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]) (1B).\nWe suggest treating adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol) with an SGLT2i (2B).\nRecommendation 3.15.1.1: In adults aged \u226550 years with eGFR <60 ml/min per 1.73 m2 but not treated with chronic dialysis or kidney transplantation (GFR categories G3a\u2013G5), we recommend treatment with a statin or statin/ezetimibe combination (1A).  \nRecommendation 3.15.1.2: In adults aged \u226550 years with CKD and eGFR \u226560 ml/min per 1.73 m2 (GFR categories G1\u2013G2), we recommend treatment with a statin (1B).",
    "ground_truth_context": "Where more accuracy is required for drug-related decision-making (e.g., dosing due to narrow therapeutic or toxic range), drug toxicity, or clinical situations where eGFRcr estimates may be unreliable, use of equations that combine both creatinine and cystatin C, or measured GFR may be indicated.",
    "is_correct": false
  },
  {
    "question": "A 55-year-old male presents with a first-time seizure lasting 7 minutes. He has no history of epilepsy. Intravenous (IV) access is difficult to obtain. What is the preferred initial pharmacologic treatment?",
    "options": [
      "Intramuscular midazolam",
      "IV lorazepam",
      "IV phenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context specifies that in adults with convulsive status epilepticus and without established IV access, intramuscular midazolam is recommended due to its superior effectiveness compared to IV lorazepam. Since the patient has a seizure lasting 7 minutes and IV access is difficult to obtain, intramuscular midazolam is the preferred initial pharmacologic treatment.",
    "reasoning_ground_truth": "For patients with convulsive status epilepticus where **IV access is difficult**, intramuscular midazolam is superior to intravenous lorazepam. IV lorazepam is a first line treatment for status epilepticus, but if an IV line cannot be established, IM midazolam is prefered. Rectal diazepam is a reasonable alternative, but midazolam has better effectiveness when IV access is not established.",
    "context": "The algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy should be apparent. A benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and\nThe optimal pharmacologic treatment for early convulsive status epilepticus is unclear.\nThe analysis addressed five questions involving adults/children with seizures lasting more than 5 minutes:  \n1. Which anticonvulsants are efficacious as initial and subsequent therapy?\n2. What adverse events are associated with anticonvulsant administration?\n3. Which is the most effective benzodiazepine?\n4. Is IV fosphenytoin more effective than IV phenytoin?\n|40-60 min|Attempt IV access and collect electrolytes, hematology, toxicology screen, (if appropriate) anticonvulsant drug levels| | |  \nFIGURE 1. Proposed treatment algorithm for status epilepticus.\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV lorazepam in adults with convulsive status epilepticus without established IV access (level A). Intravenous lorazepam is more effective than IV phenytoin in stopping seizures lasting at least 10 minutes",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old woman with a history of heavy alcohol use presents with jaundice, ascites, and confusion. She has been diagnosed with alcoholic hepatitis. What is the initial nutritional recommendation?",
    "options": [
      "Restrict fluid intake to manage ascites",
      "Initiate a high-protein, low-carbohydrate diet",
      "Start enteral nutrition with a standard formula",
      "Delay nutritional support until her liver function stabilizes"
    ],
    "correct_answer_text": "Start enteral nutrition with a standard formula",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of nutritional supplementation in patients with severe alcoholic hepatitis (ASH), highlighting that poor dietary intake and micronutrient deficiency can affect immune and gut mucosal function. It suggests that adequate calorie and protein intake through supplementation is beneficial. Starting enteral nutrition with a standard formula aligns with the recommendation for nutritional support in managing patients with alcoholic hepatitis. The other options do not directly support the need for immediate nutritional intervention as indicated in the context.",
    "reasoning_ground_truth": "The patient has signs of liver disease, which requires nutritional management. Based on the liver disease guideline, enteral nutrition should be started and is a safe route for delivery of nutritional support for patients with liver disease. Restricting fluids and or delaying nutrition may cause significant harm.",
    "context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury distinct from fatty liver disease. The recommendations are preceded by statements covering current knowledge of the underlying pathophysiology and pathobiochemistry as well as pertinent methods for the\nReduced oral intake is associated with higher mortality and nutritional supplementation is likely to result in more rapid resolution of HE and elevated serum bilirubin and lower infection risk, and severe ASH is also a hyper-metabolic state. These data support the use of adequate calorie and protein intake by supplementation. Whether alcoholic hepatitis is a state of accelerated starvation akin to cirrhosis has not been directly reported, metabolomic studies and metabolic cart studies suggest\npatients with alcohol use disorders and thiamine supplementation is used routinely in clinical practice to prevent Wernicke's encephalopathy and Korsakoff psychosis. There are very limited randomized trials in patients with alcoholic liver disease but none in severe ASH. Since patients with severe ASH have poor dietary intake and micronutrient de\ufb01ciency can affect immune and gut mucosal function, it is reasonable to replace micronutrients. Oral administration of multivitamin and zinc\n1. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol 1985;1(2):141e51.\n2. Achord JL. A prospective randomized clinical trial of peripheral amino acid-glucose supplementation in acute alcoholic hepatitis. Am J Gastroenterol 1987;82(9):871e5.\n16. Schenker S, Halff GA, editors. Nutritional therapy in alcoholic liver disease. Semin Liver Dis; 1993.\n17. Lieber CS. Alcohol, liver, and nutrition. J Am Coll Nutr 1991;10(6):602e32.\n18. Lindor KD, editor. Management of osteopenia of liver disease with special emphasis on primary biliary cirrhosis. Semin Liver Dis; 1993.",
    "ground_truth_context": "A total of 85 recommendations were made for the nutritional and metabolic management of patients with acute liver failure, severe alcoholic steatohepatitis, non-alcoholic fatty liver disease, liver cirrhosis, liver surgery and transplantation as well as nutrition associated liver injury",
    "is_correct": true
  },
  {
    "question": "A 50-year-old patient with a history of coronary artery disease underwent percutaneous coronary intervention (PCI) with drug-eluting stent placement. How long should dual antiplatelet therapy (DAPT) be continued?",
    "options": [
      "3 months",
      "6 months",
      "12 months",
      "24 months"
    ],
    "correct_answer_text": "12 months",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that in patients with acute coronary syndrome (ACS) treated with coronary stent implantation who have tolerated dual antiplatelet therapy (DAPT) without bleeding complications and are not at high bleeding risk, continuation of DAPT for longer than 12 months may be reasonable. Therefore, 12 months is the minimum duration recommended, making option C the correct answer.",
    "reasoning_ground_truth": "For most patients, 12 months of DAPT is the recommended or minimal duration of therapy following PCI with drug-eluting stent placement. The duration can vary based on the patient profile, but 12 months is the standard recommendation.",
    "context": "|IIb|ASR|In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use) continuation of DAPT for longer than 12 months may be reasonable (16,22\u201326,28,30,40,41,43,53,54,72).|\nA new risk score (the \u201cDAPT score\u201d), derived from the Dual Antiplatelet Therapy study, may be useful for decisions about whether to continue (prolong or extend) DAPT in patients treated with coronary stent implantation. Analysis of study data suggests that in patients treated for 1 year with DAPT without significant bleeding or ischemic events, the benefit/risk ratio with prolonged DAPT may be favorable for those with a high DAPT score ($2) because prolonged DAPT reduces net (ischemic plus\n|IIb|ASR|In patients with ACS (NSTE-ACS or STEMI) treated with coronary stent implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 12 months may be reasonable (16,22\u201326,28,30,40,41,43,53,54,72).|\nColors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\nsurgery in patients treated with percutaneous coronary intervention (PCI) and DAPT supersede prior corresponding recommendations in the 6 relevant guidelines. These recommendations for duration of DAPT apply to newer-generation stents and, in general, only to those not treated with oral anticoagulant therapy.",
    "ground_truth_context": "Most contemporary studies of DAPT have compared either shorter (3 to 6 months) (17\u201321) or longer (18 to 48 months) (16,22\u201326) duration of therapy with 12 months of DAPT, which is the recom-mended or minimal duration of therapy for most patients in ACC/AHA (9,13,14) and European Society of Cardiology (31\u201333) guidelines published between 2011 and 2014.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of benign prostatic hyperplasia (BPH) and hypertension presents with new-onset fatigue, constipation, and dry skin. His TSH level is elevated, and free T4 level is low. What is the appropriate initial treatment?",
    "options": [
      "Liothyronine (T3) monotherapy",
      "Combination of levothyroxine (T4) and liothyronine (T3)",
      "Levothyroxine (T4) monotherapy",
      "Thyroid-stimulating hormone (TSH) injection therapy"
    ],
    "correct_answer_text": "Levothyroxine (T4) monotherapy",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the treatment of hypothyroidism, indicating that elevated TSH levels with low free T4 levels suggest hypothyroidism. It emphasizes that treatment should be based on individual factors, but does not mention the use of T3 (liothyronine) or TSH injections as initial therapies. Levothyroxine (T4) monotherapy is the standard initial treatment for hypothyroidism, making option C the most appropriate choice based on the provided context.",
    "reasoning_ground_truth": "The patient's symptoms and lab results are consistent with primary hypothyroidism. The standard treatment is replacement with L-thyroxine (T4). Combination therapy with T3 is not recommended in the majority of cases.",
    "context": "was first described in cases of central hypothyroidism over 70 years ago (181). Although it rarely occurs, those with adrenal insufficiency, either primary or central, or at risk for it, should be treated with clinically appropriate doses of hydrocortisone until adrenal insufficiency is ruled out (182,183). In the absence of central hypothyroidism, elevated TSH levels may be seen in conjunction with normal T4 clinical hypothyroidism. However, when due to adrenal insufficiency elevated TSH levels\ndue to adrenal insufficiency elevated TSH levels fall with glucocorticoid therapy alone (54,55).\nTreatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory\u2019s reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases. Grade B, BEL 1\nWhen adrenal insufficiency is present, the diagnosis of subclinical hypothyroidism should be deferred until after glucocorticoid therapy has been instituted because TSH levels may be elevated in the presence of untreated adrenal insufficiency and may normalize with glucocorticoid therapy (54,55) (see L-thyroxine treatment of hypothyroidism).\ninitially made, but even smaller changes may be necessary to achieve goal TSH levels.",
    "ground_truth_context": "The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with a history of hypertension and type 2 diabetes presents with a 7-day history of cough, fever, and purulent nasal discharge. He reports no improvement with over-the-counter cold medications. What is the most appropriate next step in management?",
    "options": [
      "Initiate oral azithromycin for presumed community-acquired pneumonia (CAP)",
      "Prescribe a short course of oral prednisone for symptomatic relief",
      "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
      "Order a chest x-ray to evaluate for pneumonia"
    ],
    "correct_answer_text": "Begin a course of amoxicillin with or without clavulanate for possible acute bacterial rhinosinusitis (ABRS)",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context discusses the management of acute bacterial rhinosinusitis (ABRS) and indicates that antibiotics, such as amoxicillin with or without clavulanate, are appropriate for this condition. The patient presents with symptoms consistent with ABRS (cough, fever, purulent nasal discharge) and has not improved with over-the-counter medications. Therefore, option C is the most appropriate next step in management. Options A and B are not supported by the context, as antibiotics are not recommended for viral illnesses and corticosteroids are not indicated for this scenario. Option D, while it may be relevant for pneumonia, is not the immediate next step given the symptoms suggestive of ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of fever, purulent nasal discharge, and lack of improvement with over-the-counter medications suggest **acute bacterial rhinosinusitis (ABRS)**. The appropriate initial treatment is amoxicillin with or without clavulanate. While pneumonia is a differential, the primary presentation is consistent with ABRS.  Azithromycin is an alternative for penicillin allergies but is not the first-line treatment for ABRS.",
    "context": "Analgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the use of nasal saline in both physiologic and hypertonic concentrations.\nThe guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic nonallergic rhinitis, vasomotor rhinitis, invasive fungal rhinosinusitis, allergic fungal rhinosinusitis, vascular headaches, and migraines. Similarly, the guideline will not consider management of rhinosinusitis in patients with the following modifying factors but will discuss the\n|Yes|Complication present?|No|\n|Recommend symptomatic relief for ABRS|Confirm the presence or absence of nasal polyps|KAS 3|\n|Manage complication and ABRS|KAS 4|Table 6|\n|Offer watchful waiting* OR prescribe antibiotic based on shared decision-making|*requires assurance of follow-up|KAS 8|\n|Decision to proceed with watchful waiting*|Decision to proceed with initial antibiotic therapy|KAS 5|\nOral decongestants may provide symptomatic relief and should be considered barring any medical contraindications, such as hypertension or anxiety. The use of topical decongestant is likely to be palliative, but continuous duration of use should not exceed 3 to 5 days, as recommended by the manufacturers, to avoid rebound congestion and rhinitis medicamentosa. Clinical experience suggests oral antihistamines may provide symptomatic relief of excessive secretions and sneezing, although there are\nManagement of VRS is primarily directed toward relief of symptoms. Antibiotics are not recommended for treating VRS since antibiotics are ineffective for viral illness and do not provide direct symptom relief. Therefore, palliative medications\u2014such as analgesics, anti-inflammatory agents, nasal saline, decongestants, antihistamines, mucolytics, cough suppressants, and topical or oral corticosteroids\u2014may be used alone or in varying combinations for symptom relief.",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used. Saline nasal irrigation and/or topical intranasal corticosteroids are recommended.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with a history of chronic kidney disease (CKD) and hypertension is started on a new medication for her blood pressure. After two weeks she returns to the clinic for follow up reporting muscle weakness. Her labs show an increase in serum potassium. What is the most appropriate next step?",
    "options": [
      "Discontinue the new blood pressure medication immediately.",
      "Add a potassium-binding agent and continue the medication, with dietary modification",
      "Refer to nephrology for hemodialysis evaluation",
      "Prescribe an oral diuretic and schedule a follow-up in one week"
    ],
    "correct_answer_text": "Add a potassium-binding agent and continue the medication, with dietary modification",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context discusses managing hyperkalemia in patients with chronic kidney disease (CKD), emphasizing a systematic approach that includes dietary modifications and potentially adding a potassium-binding agent. Since the patient has increased serum potassium and reports muscle weakness, which can be a symptom of hyperkalemia, the most appropriate next step is to add a potassium-binding agent while also implementing dietary modifications, rather than discontinuing the medication immediately or referring for hemodialysis.",
    "reasoning_ground_truth": "The patient's hyperkalemia, likely from her new blood pressure medication, can often be managed without stopping the medication. The appropriate step would be to add a potassium-binding agent, implement individualized dietary approaches, and monitor potassium levels.  Discontinuing the medication should be considered as a last resort,.",
    "context": "Monitor serum creatinine and potassium (within 2\u20134 weeks after starting or changing dose)  \n|Normokalemia|Hyperkalemia|\u226530% decrease in eGFR|<30% decrease in eGFR|\n|---|---|---|---|\n|Increase dose of ACEi or ARB or continue on maximally tolerated dose|\u2022 Review concurrent drugs|\u2022 Review for causes of AKI|\u2022 Correct volume depletion|\n| |\u2022 Moderate dietary potassium intake|\u2022 Reassess concomitant medications (e.g., diuretics, NSAIDs)|\u2022 Consider renal artery stenosis|\n| |\u2022 Consider:| | |\nFigure 32 | Actions to manage hyperkalemia (potassium >5.5 mmol/l) in chronic kidney disease. MRA, mineralocorticoid receptor antagonists; NSAID, nonsteroidal anti-inflammatory drug; RASi, renin-angiotensin system inhibitors.\nIn people with CKD and the management of nonemergent hyperkalemia, a systematic approach of treating correctable factors (e.g., correction of severe metabolic acidosis) and understanding the role of diet and medications may provide a pragmatic framework. Figure 32 shows a stepwise practical approach to the management of hyperkalemia in CKD.\nSuggested steps in the process of medication review and reconciliation. Best practices for medication review and reconciliation in people with chronic kidney disease (CKD) include 8 steps and can be summarized as follows:  \n1. obtain an accurate medication list from the patient;\n2. evaluate whether all medications are medically necessary or whether any other medications are required;\nThe Work Group concurs with the following recommendation from the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease and the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.  \nRecommendation 3.3.2.1: We suggest that sodium intake be <2 g of sodium per day (or <90 mmol of sodium per day, or <5 g of sodium chloride per day) in people with CKD (2C).",
    "ground_truth_context": "Hyperkalemia associated with RASi use can often be managed without stopping RASi. Individualized dietary approaches should be implemented for those with hyperkalemia.",
    "is_correct": true
  },
  {
    "question": "A 72-year-old male with a history of stable ischemic heart disease (SIHD) is being discharged after a recent hospitalization for pneumonia, He has been on dual antiplatelet therapy (DAPT) for 12 months following a percutaneous coronary intervention (PCI). What is the most appropriate duration of DAPT at this point?",
    "options": [
      "Continue DAPT for an additional 12 months.",
      "Stop DAPT and continue on aspirin alone.",
      "Reduce DAPT to single antiplatelet therapy with clopidogrel",
      "Reduce DAPT to single antiplatelet therapy with aspirin"
    ],
    "correct_answer_text": "Reduce DAPT to single antiplatelet therapy with aspirin",
    "correct_answer_idx": 3.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that patients with a history of acute coronary syndrome (ACS) who have remained free of recurrent ACS for over a year transition to stable ischemic heart disease (SIHD). Since the patient has been on DAPT for 12 months following PCI and is now considered to have SIHD, the most appropriate action is to stop DAPT and continue with aspirin alone, as aspirin therapy is almost always continued indefinitely in patients with coronary artery disease.",
    "reasoning_ground_truth": "For patients with a history of ACS greater than one year prior, and who have since been stable, their condition is considered SIHD. At this point the current recommendation is to continue treatment with Aspirin alone.",
    "context": "Colors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\n|0 mo|6 mo|12 mo|\n|---|---|---|\n|Class Ilb: 12 mo may be reasonable (clopidogrel)|Class I: Resume P2Y 12 inhibitor post-op|Class I: Resume P2Y 12 inhibitor post-op complete duration of DAPT therapy after PCI|\nColors correspond to Class of Recommendation in Table 1. Patients with a history of ACS >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to SIHD. Arrows at the bottom of the figure denote that the optimal duration of prolonged DAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nA new risk score (the \u201cDAPT score\u201d), derived from the Dual Antiplatelet Therapy study, may be useful for decisions about whether to continue (prolong or extend) DAPT in patients treated with coronary stent implantation. Analysis of study data suggests that in patients treated for 1 year with DAPT without significant bleeding or ischemic events, the benefit/risk ratio with prolonged DAPT may be favorable for those with a high DAPT score ($2) because prolonged DAPT reduces net (ischemic plus",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "is_correct": false
  },
  {
    "question": "A 30-year-old female presents to the emergency department with a generalized tonic-clonic seizure lasting 7 minutes. She has no prior history of seizures, and IV access has not yet been established. What is the most appropriate initial therapy?",
    "options": [
      "Intravenous lorazepam",
      "Intramuscular midazolam",
      "Intravenous fosphenytoin",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intramuscular midazolam",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that in adults with convulsive status epilepticus, intramuscular midazolam is recommended as the initial therapy of choice when intravenous access has not been established. Since the patient in the scenario has a generalized tonic-clonic seizure lasting 7 minutes and IV access has not yet been established, IM midazolam is the most appropriate initial therapy according to the provided information.",
    "reasoning_ground_truth": "In adults with convulsive status epilepticus and without established IV access, **intramuscular midazolam** is the recommended first-line therapy because it is efficacious and rapidly administered. Intravenous lorazepam is preferred if IV access is established. Fosphenytoin is second-line therapy. Rectal diazepam is an alternative when the preferred options are not available.",
    "context": "The algorithm starts with a stabilization phase (0\u20135 minutes), which includes standard initial first aid for seizures. The initial therapy phase should begin when the seizure duration reaches 5 minutes and should conclude by the 20-minute mark when response (or lack of response) to initial therapy should be apparent. A benzodiazepine (specifically IM midazolam, IV lorazepam, or IV diazepam) is recommended as the initial therapy of choice, given their demonstrated efficacy, safety, and\nA 1983 class II study compared IV lorazepam 4 mg and IV diazepam 10 mg in adults with convulsive status epilepticus (defined as \u22653 GTC seizures in 1 hour or \u22652 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). The patients could receive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33)\nthan 5 minutes that were still occurring after paramedic arrival. Treatment success was defined as absence of seizures without additional rescue therapy at time of arrival in the emergency department, with a prespecified noninferiority margin of 10%. A total of 893 subjects (n = 748; aged 21 years or older) were randomized to either IM midazolam (n = 448) or IV lorazepam (n = 445). The primary efficacy endpoint was achieved in 73% of subjects in the IM midazolam group compared with 63% in the\nThe following conclusions were drawn. In adults, IM midazolam, IV lorazepam, IV diazepam (with or without phenytoin), and IV phenobarbital are established as efficacious at stopping seizures lasting at least 5 minutes (level A). Intramuscular midazolam has superior effectiveness compared with IV lorazepam in adults with convulsive status epilepticus without established IV access (level A). Intravenous lorazepam is more effective than IV phenytoin in stopping seizures lasting at least 10 minutes\n(22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam plus phenytoin (n = 146), phenobarbital (n = 133), or phenytoin (n = 145). Differential anticonvulsant",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with a history of alcohol abuse presents with jaundice, ascites, and altered mental status. His labs indicate acute liver failure. He is hypotensive and requires volume resuscitation. What is the most appropriate fluid for volume resuscitation at this time?",
    "options": [
      "Normal saline",
      "Albumin",
      "Hypertonic saline",
      "Dextrose 5% in water"
    ],
    "correct_answer_text": "Normal saline",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that \"most patients are volume depleted at presentation and require crystalloid volume resuscitation,\" and it mentions that \"initially normal saline may be effective.\" This directly supports the choice of normal saline as the most appropriate fluid for volume resuscitation in the scenario described. Other options like albumin, hypertonic saline, and dextrose 5% in water are not indicated in the context provided.",
    "reasoning_ground_truth": "Normal saline is the appropriate first line treatment for hypotension in acute liver failure, prior to considering albumin, which should be considered as a drug rather than as a simple resuscitative solution.",
    "context": "In the cohort of patients with ascites due to subacute liver failure or acute Budd-Chiari syndrome, elevated intra-abdominal pressure may be present. This may alter response to volume loading, in addition to increasing risk of gut dysfunction and AKI, response to fluid resuscitation needs to be assessed individually. In patients with elevated right sided cardiac pressures and ascites, further fluid therapy is likely to have limited or minimal improve venous return and improve cardiac index\n- Most patients are volume depleted at presentation and require crystalloid volume resuscitation (evidence level II-1, grade of recommendation 1).\n- Persistent hypotension requires critical care management, with application of vasopressive agents guided by appropriate monitoring techniques (evidence level II-3, grade of recommendation 1).\n- Norepinephrine is the vasopressor of choice (evidence level III, grade of recommendation 1).\nof any specific fluid for volume loading in ALF. However, general critical care literature [130\u2013133]. The choice should be guided by biochemical parameters and clinical status; initially normal saline may be effective. Hyperchloraemia should be avoided, as it has been associated with increased risk of renal failure and other morbidities with Ringers lactate (recognising the risk of hypotonicity) or a balanced solution as required. Balanced solutions are buffered with either bicarbonate or\nfalls in lactate may allow assessment of volume responsiveness [114]. However, subsequent lactate reflects a composite measure of both increased production (peripheral aerobic glycolysis and decreased clearance due to hepatic metabolic capacity) [115]. Oral intake is encouraged if the patient is not too nauseated, but if HE progresses this should be avoided as patients may require urgent intubation. Insertion of nasogastric tubes prior to intubation is normally avoided due to risk of vomiting,\n|Elevated lactate unresponsive to fluid resuscitation|Shrinking liver size| |",
    "ground_truth_context": "If used in this context, albumin should be viewed more as a drug, than as a resuscitative solution.",
    "is_correct": true
  },
  {
    "question": "A 60-year-old male with a history of primary open-angle glaucoma (POAG) has been using prescribed eye drops for the past year. During his annual ophthalmology visit, his intraocular pressure (IOP) is still elevated, and his optic nerve shows progressive damage. He reports variable adherence to his medication regimen. What is the most appropriate next step in management?",
    "options": [
      "Increase the dose of his current eye drops.",
      "Add a second medication to his current eye drops",
      "Review patient education materials and discuss adherence.",
      "Refer for surgical intervention immediately."
    ],
    "correct_answer_text": "Review patient education materials and discuss adherence.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of patient education and adherence to medication regimens in managing POAG. Since the patient reports variable adherence to his medication, reviewing patient education materials and discussing adherence is a crucial step before considering changes to his medication regimen or surgical intervention. The context also notes that adherence may be improved through repeated instruction and counseling about proper techniques for using medication.",
    "reasoning_ground_truth": "Patient education and adherence are crucial in the management of POAG. Before escalating therapy, it's essential to ensure the patient understands the importance of medication adherence and how to use them correctly.",
    "context": "The goals of managing patients with POAG are as follows:  \n- Control of IOP in the target range\n- Stable optic nerve/RNFL status\n- Stable visual fields  \nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80, 82, 306-319\nPatient education through oral, written, and online information and informed participation in treatment decisions may improve adherence357 and overall effectiveness of glaucoma management. Adherence to medical therapy may be handicapped when patients run out of medication, due to inadvertent drop wastage or inability to properly instill eye drops, before they are permitted to refill their prescription. One study found this was more likely for patients who self-administered eye drop medications\nIf a drug fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding medication is appropriate until the desired IOP level is attained.259 Since some studies have shown that adding a second medication decreased adherence to glaucoma treatment,347, 348 fixed combination therapy may improve patient adherence, and reduce exposure to preservatives, although it is not recommended for initial treatment in most circumstances. However, when the\nInstilling eye drops correctly is difficult for many patients, and their ability to do so may worsen with aging, comorbidities, and as glaucoma progresses.355, 356 Repeated instruction and counseling about proper techniques for using medication, including waiting at least 5 minutes between multiple drop regimens as well as a clearly written medication regimen and follow-up telephone calls or smartphone reminders, may improve adherence to therapy.353, 357 A Cochrane Systematic Review in 2013\nIf the diagnosis or management of POAG is in question, or if the condition is refractory to treatment, consultation with or referral to an ophthalmologist with special training or experience in managing glaucoma should be considered. Patients with substantial visual impairment or blindness can be referred for and encouraged to use appropriate vision rehabilitation and social services.703 More information on vision rehabilitation, including materials for patients, is available at",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with rheumatoid arthritis (RA) has been on methotrexate for three months. She reports improvement in joint pain, but still experiences morning stiffness and fatigue, indicating moderate disease activity. What is the most appropriate next step?",
    "options": [
      "Add a biologic DMARD to her current methotrexate.",
      "Increase the dose of methotrexate",
      "Add a short course of oral prednisone to the methotrexate.",
      "Continue methotrexate monotherapy for another 3 months"
    ],
    "correct_answer_text": "Continue methotrexate monotherapy for another 3 months",
    "correct_answer_idx": 3.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen. Since the patient has been on methotrexate for three months and still experiences moderate disease activity (indicated by morning stiffness and fatigue), increasing the dose of methotrexate is a reasonable next step to enhance efficacy, as the recommendation allows for dose escalation to provide additional efficacy. Other options do not align with the context's guidance on managing moderate disease activity after an initial treatment period.",
    "reasoning_ground_truth": "According to guidelines, initial treatment for moderate-to-high RA is with **methotrexate monotherapy** . A combination approach may be considered after a trial of methotrexate. This patient has not had an adequate trial on methotrexate as she is only 3 months into treatment and still showing moderate disease activity.",
    "context": "Methotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nRA requires early evaluation, diagnosis, and management.Treatment decisions should follow a shared decision-making process.Treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen.Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options\n* PICO = population, intervention, comparator, and outcomes; Supp. App. 2 = Supplementary Appendix 2, available on the Arthritis Care & Research website at http://onlinelibrary.wiley.com/doi/10.1002/acr.24596/abstract; DMARD = disease-modifying antirheumatic drug.  \n\u2020 This recommendation refers only to the initial prescribing of methotrexate and is not meant to limit further dose escalation, which often provides additional efficacy.\nto initiating methotrexate (49). In addition, more frequent monitoring should be performed in this patient population (every 4 to 8 weeks). The recommendation is conditional because patients\u2019 and clinicians\u2019 risk tolerance varies.\nvoting panel favored a conditional recommendation to initiate methotrexate therapy in this clinical setting because of the vital role of this DMARD in the overall treatment of RA and lack of other comparable therapies without pulmonary risks.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": false
  },
  {
    "question": "A 22-year-old male presents with urethral discharge and dysuria for 3 days. A gram stain of the discharge shows gram-negative diplococci. Which of the following is the recommended treatment approach?",
    "options": [
      "Oral azithromycin monotherapy",
      "Intramuscular ceftriaxone and oral azithromycin",
      "Oral doxycycline for 7 days",
      "Oral ciprofloxacin for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone and oral azithromycin",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that for gonococcal infections, particularly in symptomatic men with urethritis (as in the case of the 22-year-old male), the recommended treatment approach includes a regimen that is WHO-recommended. While the specific regimens are not detailed in the context, the presence of gram-negative diplococci in the gram stain suggests a gonococcal infection, which is typically treated with a combination of intramuscular ceftriaxone and oral azithromycin. This aligns with current guidelines for treating gonorrhea, making option B the most appropriate choice.",
    "reasoning_ground_truth": "For gonococcal infections, the recommended treatment is **intramuscular ceftriaxone plus oral azithromycin**. This combination is used to address potential resistance and co-infection with chlamydia.",
    "context": "Since laboratory diagnostic tests are not available in the majority of countries, diagnosis is often made clinically, based on the presence of symptoms such as vaginal and urethral discharge. Presumptive treatment is sometimes provided to those at high risk of gonococcal infection, if indicated based on local epidemiological patterns.\nGram-stained smears can provide a presumptive diagnosis of gonorrhoea, especially among symptomatic men with urethritis. In low-income settings, Gram stains may provide a less expensive alternative to NAATs for symptomatic men. However, only 50\u201370% of asymptomatic infections in men are positive on Gram stain. Gram stain diagnosis for cervical and rectal infection is less reliable and pharyngeal samples should not be analysed.\nUncomplicated gonococcal infection commonly manifests as urethritis in men with symptoms of urethral discharge and dysuria. On examination, the urethral discharge may range from scanty and mucoid to copious and purulent. Gonorrhoea is often asymptomatic in women; less than half of infected women complain of non-specific symptoms such as abnormal vaginal discharge, dysuria, lower abdominal discomfort and dyspareunia. The most common clinical signs are vaginal discharge and cervical friability due\nWe recommend obtaining sputum for Gram stain and culture in situations when risk factors for MRSA or P. aeruginosa present, both when initial empiric therapy is expanded to cover these pathogens and when it is not expanded. In the former case, negative microbiological test results may be used to deescalate therapy, and in the latter case, positive microbiological test results may be used to adjust therapy. As discussed later, although there are numerous studies identifying individual risk\nConditional recommendation, very low quality evidence  \nIn people with gonococcal infections who have failed treatment, the WHO STI guideline suggests the following options.  \n- If reinfection is suspected, re-treat with a WHO-recommended regimen, reinforce sexual abstinence or condom use, and provide partner treatment.\n- If treatment failure occurred after treatment with a regimen not recommended by WHO, re-treat with a WHO-recommended regimen.",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male, recently hospitalized for an acute exacerbation of COPD, is being considered for discharge. He has been immobile for most of his hospital stay and has no other identified risk factors for VTE. Which VTE prophylaxis is recommended?",
    "options": [
      "Pharmacologic prophylaxis with subcutaneous heparin",
      "Mechanical prophylaxis with intermittent pneumatic compression devices",
      "Both pharmacologic and mechanical prophylaxis",
      "No VTE prophylaxis required due to low risk."
    ],
    "correct_answer_text": "Pharmacologic prophylaxis with subcutaneous heparin",
    "correct_answer_idx": 0.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context states that the ASH guideline panel specifically recommends against VTE prophylaxis in medical outpatients with minor provoking factors for VTE, such as immobility, which applies to the patient in the scenario. Since the patient has been immobile but has no other identified risk factors for VTE, the recommendation is to not use VTE prophylaxis, aligning with the guidance provided in the context.",
    "reasoning_ground_truth": "According to recommendations acutely ill medical patients such as those in this case,  should receive pharmacologic prophylaxis, such as heparin.",
    "context": "Should VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nprophylaxis for persons without risk factors. For long-distance travelers at increased risk for VTE, the ACCP recommended 15- to 30-mm Hg below-knee graduated compression stockings, frequent ambulation, calf muscle exercise, or sitting in an aisle seat. They recommended against the use of aspirin or anticoagulants. The ASH panel recommended LMWH or graduated compression stockings and the use of aspirin if these were not feasible or available.\nIn medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness, infection), the ASH guideline panel suggests not using VTE prophylaxis (conditional recommendation, very low certainty in the evidence of effects \u00c5\u25ef\u25ef\u25ef).\nRecommendation 16. In medical outpatients with minor provoking risk factors for VTE (eg, immobility, minor injury, illness, infection), the ASH guideline panel suggests not using VTE prophylaxis (conditional recommendation, very low certainty in the evidence of effects \u00c5\u25ef\u25ef\u25ef).  \nRecommendation 17. In long-distance (.4 hours) travelers without risk factors for VTE, the ASH guideline panel suggests not using graduated compression stockings, LMWH, or aspirin for VTE prophylaxis.\nAddressed combination mechanical and pharmacological prophylaxis over either alone and suggested against the combination. The ASH panel and ACCP recommended against prophylaxis in chronically immobilized outpatients or nursing home residents. The ASH panel also specifically recommended against prophylaxis in outpatients with minor provoking factors for VTE. The ACCP and the ASH panel considered long-distance travelers and advised against prophylaxis for persons without risk factors. For",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "is_correct": false
  },
  {
    "question": "A 70-year-old female presents with cough, fever and shortness of breath. She is diagnosed with community-acquired pneumonia (CAP) and is admitted to the hospital. Her blood cultures taken on admission come back negative. What is the most appropriate step?",
    "options": [
      "Continue antibiotics for 7 days, regardless of clinical stability",
      "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
      "Discontinue antibiotics immediately due to negative blood culture results.",
      "Switch antibiotics to oral therapy."
    ],
    "correct_answer_text": "Continue antibiotics until a validated measure of clinical stability is achieved and for no less than 5 days.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context emphasizes the importance of clinical stability in determining the duration of antibiotic treatment for patients with community-acquired pneumonia (CAP). It suggests that antibiotics should be continued until a validated measure of clinical stability is achieved and for no less than 5 days. This aligns with option B, which states to continue antibiotics until clinical stability is validated and for at least 5 days. The other options do not align with the recommendations provided in the context.",
    "reasoning_ground_truth": "The duration of antibiotic therapy should be guided by a validated measure of clinical stability and continued for at least 5 days. Negative blood cultures do not indicate discontinuing treatment.",
    "context": "We recommend not obtaining blood cultures in adults with CAP managed in the outpatient setting (strong recommendation, very low quality of evidence).  \nWe suggest not routinely obtaining blood cultures in adults with CAP managed in the hospital setting (conditional recommendation, very low quality of evidence).\nGram stain and culture: in hospitalized patients with severe CAP, and when strong risk factors for MRSA and P. aeruginosa are identified, unless local etiological data have already shown these pathogens are very infrequently identified in patients with CAP. Patients who have severe CAP requiring intubation should have lower respiratory tract samples, such as endotracheal aspirates, sent for Gram stain and culture promptly after intubation, particularly as these patients may be more likely to\nRecommendation. We recommend not obtaining sputum Gram stain and culture routinely in adults with CAP managed in the outpatient setting (strong recommendation, very low quality of evidence).\nProcalcitonin has been used to guide initiation of antibiotics in patients with lower respiratory infections, but many of these studies are not restricted to patients with radiographically confirmed pneumonia. Some patients with low procalcitonin levels have CAP and have been safely treated without antibiotics (35), but these represent small subgroups, raising concerns about the safety of widely using such a strategy.\nRationale for the recommendation. In balancing the lack of evidence supporting routine sputum culture with the desire for improved antimicrobial stewardship, the committee voted to continue the stance of previous guidelines in recommending neither for nor against routinely obtaining sputum Gram stain and culture in all adults with CAP managed in the hospital setting. Whether to culture patients or not should be determined by individual clinicians on the basis of clinical presentation, local",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 62-year-old man with a history of heavy alcohol use presents with new onset jaundice, ascites, and confusion. His labs are suggestive of acute liver failure (ALF). He is hemodynamically stable and is being admitted for ongoing care. Which of the following is the preferred approach for managing his encephalopathy?",
    "options": [
      "Start intravenous steroids to reduce cerebral edema.",
      "Initiate lactulose and rifaximin.",
      "Maintain serum osmolarity above 320 mOsmol using hypertonic saline.",
      "Monitor intracranial pressure (ICP) without intervention"
    ],
    "correct_answer_text": "Initiate lactulose and rifaximin.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context discusses the management of acute liver failure (ALF) and mentions that patients with hyper-acute ALF may be at risk for cerebral edema and elevated ammonia levels. It emphasizes the importance of monitoring arterial ammonia levels and suggests that low-dose enteral nutrition (EN) should be initiated when metabolic derangements are controlled. While the context does not explicitly mention lactulose and rifaximin, these are standard treatments for hepatic encephalopathy, which aligns with the management of the patient's confusion and encephalopathy due to ALF. The other options (A, C, D) do not directly relate to the preferred management approach for encephalopathy in this context.",
    "reasoning_ground_truth": "The preferred approach for treating hepatic encephalopathy in ALF involves **lactulose and rifaximin**, which reduce the production and absorption of neurotoxins. Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol. ICP should be monitored and treatment initiated as necessary using interventions such as hypertonic saline or intravenous mannitol.",
    "context": "In general, decisions on when to initiate nutrition support and which route to use are made in accordance with the recommendations for nutrition support in other intensive care unit (ICU) patient groups. Three subtypes of ALF can be classified according to their clinical course. In \u2018hyper-acute\u2019 liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or\n6. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985;5(5):282e9.\n4. Cerra FB, Cheung NK, Fischer JE, Kaplowitz N, Schiff ER, Dienstag JL, et al. Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial. J Parenter Enteral Nutr 1985;9(3):288e95.\n5. Fiaccadori F. Branched-chain enriched amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital J Gastroenterol 1985;17:5e10.\nPatients with hyper-acute ALF and elevated and sustained arterial ammonia levels (>150 mMol/l) may be at increased risk of cerebral edema and development of intra-cranial hypertension [177,178]. In this specific setting where there may be short-lived but current clinical practice adopted in many European liver units demonstrates the safety and feasibility of EN in ALF patients.  \nStrong consensus (100% agreement)  \nRecommendation 11\nAccording to ESICM guidelines [179] low dose EN should be started when acute, immediately life-threatening metabolic derangements are controlled with or without liver support strategies, independent on grade of encephalopathy. Arterial ammonia levels should be monitored.",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF. Serum osmolarity should be maintained below 320 mOsmol with RRT as required.",
    "is_correct": true
  },
  {
    "question": "A 48-year-old female with a 10-year history of type 1 diabetes is being screened for chronic kidney disease (CKD). Which test should be used to start the screening process, given her history?",
    "options": [
      "Urine dipstick for protein",
      "Serum creatinine and calculate eGFR",
      "24-hour urine collection for albumin",
      "Kidney biopsy"
    ],
    "correct_answer_text": "Serum creatinine and calculate eGFR",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that for screening for chronic kidney disease (CKD), individuals at risk, such as those with type 1 diabetes, should be tested using both urine albumin measurement and assessment of glomerular filtration rate (GFR). Since the patient has a 10-year history of type 1 diabetes, the appropriate initial test to start the screening process would be to measure serum creatinine and calculate the estimated GFR (eGFR), as indicated in the context.",
    "reasoning_ground_truth": "The initial screening test for CKD is an **eGFR calculated using serum creatinine**. While urine albumin is part of CKD evaluation, eGFR is the initial and primary test used.",
    "context": "The highest priority conditions for CKD detection are hypertension, diabetes, and CVD, including heart failure. For diabetes, the ADA and KDIGO recommend annual screening of people with diabetes for CKD. CKD screening should start at diagnosis of T2D because evidence of CKD is often already apparent at this time. For T1D, screening is recommended commencing 5 years after diagnosis. A second important group includes people with recent AKI or acute kidney disease (AKD), particularly multiple\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).  \nPractice Point 1.1.1.2: Following incidental detection of elevated urinary albumin-to-creatinine ratio (ACR), hematuria, or low estimated GFR (eGFR), repeat tests to confirm presence of CKD.\nPractice Point 1.1.1.1: Test people at risk for and with chronic kidney disease (CKD) using both urine albumin measurement and assessment of glomerular filtration rate (GFR).\nin primary care and in other specialties, such as endocrinology, cardiology, and oncology, rather than restricted to nephrologists. We strongly support efforts aimed at the early detection and treatment of CKD among people at high risk for CKD, including those with hypertension, diabetes, and CVD. Screening efforts in these and other populations should include assessments of GFR (estimated or in certain situations measured [see Section 1.2] and albuminuria [or surrogate, see Section 1.3]).\nCKD fits the World Health Organization (WHO) criteria for an early detection program. Given that chronic disease detection and prevention frameworks have been deployed for other disease and risk factor conditions, in our view, CKD detection strategies should be implemented for high-risk people.",
    "ground_truth_context": "As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr.",
    "is_correct": true
  },
  {
    "question": "A 78-year-old male is diagnosed with acute bacterial rhinosinusitis (ABRS). He has a known penicillin allergy. Which antibiotic is most appropriate?",
    "options": [
      "Oral amoxicillin/clavulanate",
      "Oral azithromycin",
      "Oral doxycycline",
      "Topical intranasal corticosteroids"
    ],
    "correct_answer_text": "Oral doxycycline",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that for penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative for empiric antimicrobial therapy. Since the patient has a known penicillin allergy, oral amoxicillin/clavulanate (Option A) is not appropriate. Oral azithromycin (Option B) is not mentioned as a recommended alternative in the context. Topical intranasal corticosteroids (Option D) are not antibiotics and do not address the bacterial infection. Therefore, the most appropriate choice for this patient is oral doxycycline (Option C).",
    "reasoning_ground_truth": "For patients with a penicillin allergy, **doxycycline** is a recommended alternative for treating ABRS. Azithromycin may be considered as an alternative to doxycycline. While topical intranasal corticosteroids are recommended for symptom relief, they are not an alternative to antibiotics for ABRS.",
    "context": "For penicillin-allergic patients, either doxycycline or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is recommended as an alternative agent for empiric antimicrobial therapy. Fluoroquinolones, however, are not recommended for first-line therapy of ABRS in patients without penicillin allergy because outcomes are comparable to amoxicillin-clavulanate, and adverse events are higher in some trials. Combination therapy with clindamycin plus a third-generation oral cephalosporin\n|5. Choice of antibiotic for ABRS|If a decision is made to treat ABRS with an antibiotic agent, the clinician should prescribe amoxicillin with or without clavulanate as first-line therapy for 5 to 10 days for most adults.|\nThe use of high-dose amoxicillin with clavulanate (2 g orally twice daily or 90 mg/kg/d orally twice daily) is recommended15 for adults with ABRS who are at a high risk of being infected with an amoxicillin-resistant organism. High-dose amoxicillin is preferred over standard-dose amoxicillin primarily to cover penicillin nonsusceptible (PNS) *Streptococcus pneumoniae. This risk exists in those from geographic regions with high endemic rates (>10%) of invasive PNS S pneumoniae*, those with\n|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory symptoms, or b. symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening)|\nNo significant differences have been found in clinical outcomes for ABRS among different antibiotic agents. A systematic review and 2 RCTs of sinusitis patients with radiologic or bacteriologic confirmation found no significant difference in rates of clinical resolution for patients treated with amoxicillin or amoxicillin-clavulanate compared with cephalosporins or macrolides. Another review found no differences in 11 comparative meta-analyses but did find a small decrease in failure rates for",
    "ground_truth_context": "For acute bacterial rhinosinusitis (ABRS), amoxicillin with or without clavulanate is a recommended antibiotic. If a patient is allergic to penicillin, doxycycline or a respiratory quinolone can be used.",
    "is_correct": true
  },
  {
    "question": "A 28-year-old pregnant female at 32 weeks gestation is admitted to the hospital with a first-time seizure lasting 8 minutes.  IV access has been obtained. What is the preferred initial treatment for her convulsive status epilepticus?",
    "options": [
      "Intravenous phenytoin",
      "Intramuscular midazolam",
      "Intravenous lorazepam",
      "Rectal diazepam"
    ],
    "correct_answer_text": "Intravenous lorazepam",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that lorazepam is a treatment option for status epilepticus, specifically noting its use in a study where it was administered intravenously. The definition of status epilepticus includes continuous seizures lasting longer than 5 minutes, which applies to the patient's 8-minute seizure. Therefore, intravenous lorazepam is the preferred initial treatment for her convulsive status epilepticus. Other options like phenytoin and midazolam are not indicated as first-line treatments in the provided context.",
    "reasoning_ground_truth": "For a patient with convulsive status epilepticus with established IV access, **intravenous lorazepam** is the recommended initial therapy. Intramuscular midazolam is preferred when IV access has not yet been established. Phenytoin is an acceptable alternative second line medication. Rectal diazepam is considered an alternative when the preferred options are not available.",
    "context": "The optimal pharmacologic treatment for early convulsive status epilepticus is unclear.\n(22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam plus phenytoin (n = 146), phenobarbital (n = 133), or phenytoin (n = 145). Differential anticonvulsant\nA second class I study in adults (older than 18 years) with status epilepticus was initiated outside the hospital by paramedics (23). In this 2001 study, patients were randomized to receive 2 mg IV lorazepam or 5 mg IV diazepam or IV placebo in the ambulance. The protocol allowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes\n|40-60 min|Attempt IV access and collect electrolytes, hematology, toxicology screen, (if appropriate) anticonvulsant drug levels| | |  \nFIGURE 1. Proposed treatment algorithm for status epilepticus.\nA 1983 class II study compared IV lorazepam 4 mg and IV diazepam 10 mg in adults with convulsive status epilepticus (defined as \u22653 GTC seizures in 1 hour or \u22652 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). The patients could receive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33)",
    "ground_truth_context": "In adults with convulsive status epilepticus, intramuscular midazolam, intravenous lorazepam, intravenous diazepam and intravenous phenobarbital are established as efficacious as initial therapy (Level A). Intra-muscular midazolam has superior effectiveness compared to intravenous lorazepam in adults with convulsive status epilepticus without established intravenous access (Level A).",
    "is_correct": true
  },
  {
    "question": "A 52-year-old male with a history of chronic liver disease presents with worsening ascites and is being evaluated for possible liver transplant. What type of renal replacement therapy (RRT) is preferred if the patient develops acute kidney injury?",
    "options": [
      "Intermittent hemodialysis",
      "Continuous renal replacement therapy (CRRT)",
      "Peritoneal dialysis",
      "No RRT is indicated at this time"
    ],
    "correct_answer_text": "Continuous renal replacement therapy (CRRT)",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context discusses the use of renal replacement therapy (RRT) in patients with acute liver failure (ALF) and highlights that RRT may be offered to manage conditions such as hyperammonaemia and acidosis. It specifically mentions continuous renal replacement therapies (CRRT) in the context of liver failure, suggesting that CRRT is preferred for managing acute kidney injury in these patients. Therefore, option B is directly supported by the context.",
    "reasoning_ground_truth": "For patients with acute liver failure and acute kidney injury, **continuous renal replacement therapy (CRRT)** is preferred over intermittent hemodialysis to avoid metabolic and hemodynamic fluctuations.",
    "context": "and, as such, may be better referred to as liver or metabolic replacement therapy. Slack et al. have shown a clear correlation between creatinine clearance and ammonia clearance [210]. Therefore, early consideration of RRT should be undertaken in those ALF patients with markedly elevated ammonia and/or progressive HE.\n[211] Davenport A. Is there a role for continuous renal replacement therapies in patients with liver and renal failure? Kidney Int Suppl 1999;72:S62\u2013S66.  \n[212] Schultheiss C, Saugel B, Phillip V, Thies P, Noe S, Mayr U, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012;16:R162.\nin other forms of hyperacute liver failure. The timing of institution of RRT in the context of ALF has the potential to cause conflict between speciality groups involved in the care for these patients [209]. RRT is normally instituted in the context of uraemia, fluid overload and hyperkalaemia. In the context of ALF, however, RRT may be offered to manage acidosis, hyperammonaemia and sodium imbalance, facilitate temperature and metabolic control and, as such, may be better referred to as liver\n[209] Bagshaw SM, Uchino S, Kellum JA, Morimatsu H, Morgera S, Schetz M, et al. Association between renal replacement therapy in critically ill patients with severe acute kidney injury and mortality. J Crit Care 2013;28:1011\u20131018.  \n[210] Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int 2014;34:42\u201348.\n[207] Angeli P, Gin\u00e8s P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62:968\u2013974.  \n[208] Leithead JA, Ferguson JW, Bates CM, Davidson JS, Lee A, Bathgate AJ, et al. The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut 2009;58:443\u2013449.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations.",
    "is_correct": true
  },
  {
    "question": "A 68-year-old male with established primary open-angle glaucoma (POAG) is using a single eye drop medication. His intraocular pressure (IOP) remains elevated at his follow up appointment. What is the next step in the treatment of this patient?",
    "options": [
      "Increase the dose of his current eye drop",
      "Add a second medication to his current eye drop",
      "Consider laser trabeculoplasty",
      "Consider surgery."
    ],
    "correct_answer_text": "Add a second medication to his current eye drop",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that if IOP is poorly controlled on several medications, glaucoma surgery may be indicated. However, since the patient is currently using a single eye drop medication and his IOP remains elevated, the next logical step would be to add a second medication to his current eye drop, as this aligns with the goal of controlling IOP in the target range. Increasing the dose of the current medication (Option A) is not mentioned as a recommended step in the context, and options C and D suggest more invasive procedures that are not indicated at this stage given the current treatment regimen.",
    "reasoning_ground_truth": "When a single medication is not adequate to manage POAG, adding a second medication is the preferred next step in management before considering laser trabeculoplasty or surgery.",
    "context": "Patients with POAG who have visually significant cataracts have a range of options available. If IOP control is at target on one or two medications, cataract surgery alone may be adequate, with the additional benefit that it may lower IOP slightly. If IOP is poorly controlled on several medications or there is evidence of glaucomatous progression in a patient with a moderate cataract, glaucoma surgery may be indicated initially, with the plan to perform cataract surgery once IOP is adequately\nThe goals of managing patients with POAG are as follows:  \n- Control of IOP in the target range\n- Stable optic nerve/RNFL status\n- Stable visual fields  \nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80, 82, 306-319\nEstablished risk factors for primary open-angle glaucoma (POAG) include older age, African race or Latino/Hispanic ethnicity, elevated intraocular pressure (IOP), family history of glaucoma, low ocular perfusion pressure, type 2 diabetes mellitus, myopia, and thin central cornea.  \nPrimary open-angle glaucoma patients often have untreated IOP consistently within the normal range (i.e., normal tension glaucoma). Lowering pressure in these patients is beneficial.\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and they need to be instilled only once daily.75, 326-328\nGuidelines for follow-up of patients with POAG are summarized in Table 7. These recommendations apply to ongoing glaucoma management and not to visits for other purposes. The purpose of follow-up examination is to evaluate IOP level, visual field status, and optic disc appearance as well as ONH, RNFL, and macular imaging to determine if progressive damage has occurred.  \n**Table 7: Consensus-Based Guidelines for Follow-Up Glaucoma Status**",
    "ground_truth_context": "Patient education and informed participation in treatment decisions may improve adherence.",
    "is_correct": true
  },
  {
    "question": "A 58-year-old female with rheumatoid arthritis (RA) is currently treated with methotrexate, but is still having persistent moderate disease activity. Which of the following is the next recommended step?",
    "options": [
      "Add a targeted synthetic DMARD (tsDMARD)",
      "Increase the dose of methotrexate",
      "Add a biologic DMARD (bDMARD)",
      "Add a short course of oral prednisone"
    ],
    "correct_answer_text": "Add a biologic DMARD (bDMARD)",
    "correct_answer_idx": 2.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context states that treatment decisions should be reevaluated within a minimum of 3 months based on the efficacy and tolerability of the DMARD(s) chosen. Since the patient is currently treated with methotrexate and still has persistent moderate disease activity, the next recommended step would be to increase the dose of methotrexate, as the recommendation refers to the initial prescribing of methotrexate and does not limit further dose escalation, which often provides additional efficacy.",
    "reasoning_ground_truth": "According to the guidelines, if a patient on methotrexate monotherapy continues to have moderate disease activity, the next recommended step would be to add a **biologic DMARD** or a targeted synthetic DMARD.",
    "context": "RA requires early evaluation, diagnosis, and management.Treatment decisions should follow a shared decision-making process.Treatment decisions should be reevaluated within a minimum of 3 months based on efficacy and tolerability of the DMARD(s) chosen.Disease activity levels refer to those calculated using RA disease activity measures endorsed by the ACR (10).Recommendations are intended for the general RA patient population and assume that patients do not have contraindications to the options\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nThe recommendation statements in this update are not directly comparable to the ACR 2015 guidelines (1) because they do not retain the early versus established RA subgroups. Nevertheless, there are some notable differences. First, the 2015 guidelines recommend csDMARD monotherapy, preferably with methotrexate, for patients with both low and moderate/high disease activity, whereas this update recommends an initial trial of hydroxychloroquine or sulfasalazine for those with low disease activity.\nvoting panel favored a conditional recommendation to initiate methotrexate therapy in this clinical setting because of the vital role of this DMARD in the overall treatment of RA and lack of other comparable therapies without pulmonary risks.\n* PICO = population, intervention, comparator, and outcomes; Supp. App. 2 = Supplementary Appendix 2, available on the Arthritis Care & Research website at http://onlinelibrary.wiley.com/doi/10.1002/acr.24596/abstract; DMARD = disease-modifying antirheumatic drug.  \n\u2020 This recommendation refers only to the initial prescribing of methotrexate and is not meant to limit further dose escalation, which often provides additional efficacy.",
    "ground_truth_context": "Methotrexate monotherapy is conditionally recommended over the combination of methotrexate plus a bDMARD or tsDMARD.",
    "is_correct": false
  },
  {
    "question": "A 26-year-old male is diagnosed with uncomplicated gonorrhea. He has no known drug allergies. What is the recommended treatment regimen?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100 mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that updated treatment recommendations for gonorrhea include dual therapy, particularly with ceftriaxone and azithromycin. It mentions that in settings where local resistance data are not available, the WHO STI guideline suggests dual therapy over single therapy for genital or anorectal gonorrhea. Therefore, the recommended treatment regimen for uncomplicated gonorrhea in this case is intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose, which aligns with option C. Options A, B, and D do not reflect the current recommendations for treating uncomplicated gonorrhea as outlined in the context.",
    "reasoning_ground_truth": "For uncomplicated gonorrhea, the current recommendation is **intramuscular ceftriaxone plus oral azithromycin**, given as a single dose.",
    "context": "Updated treatment recommendations based on the most recent evidence are included for the most important common conditions caused by N. gonorrhoeae. Recommendations were not updated for rare conditions and other conditions for which no new information became available since the 2003 WHO STI guidelines were issued. Treatment recommendations for the following conditions caused by N. gonorrhoeae are included in these guidelines:  \n- genital and anorectal infections\n- oropharyngeal infections\ntransmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even though high levels of resistance to quinolones are reported in most countries and these medicines have been withdrawn from all international guidelines. Decreased susceptibility to the extended spectrum (third-generation) cephalosporins, another recommended first-line treatment in the 2003 guidelines, is becoming more widespread and several countries have reported treatment\nIn settings where local resistance data are not available, the WHO STI guideline suggests dual therapy over single therapy for people with genital or anorectal gonorrhoea.\nC. trachomatis, increasing the dosage of ceftriaxone to 250 mg for treatment of N. gonorrhoeae with continued monitoring of antimicrobial susceptibility, and consideration of whether azithromycin (2 g, single dose) should be recommended in early syphilis (16).\n500 mg IM x 1; ceftriaxone 250 mg IM x 1; ceftriaxone 125 mg IM x 1; cefixime 400 mg orally x 1; cefixime 800 mg orally x 1; cefixime 400 mg orally x 2; or gentamicin 240 mg IM x 1|Critical: Microbiological cure, clinical cure, N. gonorrhoeae antimicrobial in vitro resistance, compliance Important: STI complications, side-effects (including allergy, toxicity), quality of life, transmission to partners|",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female is hospitalized for an acute illness. She has no prior history of venous thromboembolism (VTE). She is being considered for discharge. What should the VTE risk stratification for her take into account?",
    "options": [
      "Her age alone",
      "Her length of stay alone.",
      "Her risk factors for VTE and length of stay.",
      "Her comorbidities alone."
    ],
    "correct_answer_text": "Her risk factors for VTE and length of stay.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that medical inpatients have a heterogeneous population in terms of VTE risk and that risk factors for VTE should be considered when stratifying risk. It specifically mentions that the guidelines address methods to prevent VTE in adult in-hospital and outpatient medical populations, implying that both risk factors and length of stay are relevant for VTE risk stratification. Therefore, option C, which includes both risk factors for VTE and length of stay, is the most comprehensive and supported by the context.",
    "reasoning_ground_truth": "VTE risk assessment considers **both risk factors for VTE and length of stay**. Age and comorbidities are risk factors that should also be considered along with the length of stay. ",
    "context": "Venous thromboembolism (VTE) is the third most common cardiovascular diagnosis, with an incidence rate of \u223c1 in 1000 annually in middle age and increasing to nearly 1% annually in nonagenarians. About 50% of all VTE events occur as a result of a current or recent hospital admission for surgery or acute medical illness. Hospital-acquired VTE is preventable, with interventions including anticoagulants and mechanical measures, including compression stockings and intermittent pneumatic compression.\nVenous thromboembolism (VTE) is the third most common vascular disease. Medical inpatients, long-term care residents, persons with minor injuries, and long-distance travelers are at increased risk.\n\u00a9 2018 by The American Society of Hematology  \nOther nonhospitalized medical populations that are at increased risk for VTE include long-term care residents, frail persons, those with minor injuries, and long-distance travelers, particularly those with preexisting VTE risk factors. These guidelines addressed methods to prevent VTE in these adult in-hospital and outpatient medical populations who are not on chronic anticoagulants for other indications.\ncare patients or outpatients with minor VTE risk factors. The panel conditionally recommended use of graduated compression stockings or low-molecular-weight heparin in long-distance travelers only if they are at high risk for VTE.\nThe panel discussed which acutely ill medical inpatients should be considered in these guidelines. Medical inpatients are a heterogeneous population in terms of VTE risk, but these patients have conventionally been subject to universal, or group-based, VTE-prevention strategies. We defined acutely ill medical patients as patients hospitalized for a medical illness. Critically ill patients were defined as suffering from an immediately life-threatening condition requiring hospitalization in an",
    "ground_truth_context": "Parenteral anticoagulant vs no parenteral anticoagulant in acutely ill medical patients. Summary of the evidence. We found 17 systematic reviews that addressed this question,51-67 with 25 studies29,30,68-89",
    "is_correct": true
  },
  {
    "question": "A 67-year-old male with a history of COPD and recent hospitalization for pneumonia is now clinically stable and ready for discharge. What is the recommended duration for his antibiotic treatment?",
    "options": [
      "Continue antibiotics for 7 days.",
      "Continue antibiotics for 10 days.",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days",
      "Discontinue antibiotics at the time of discharge."
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days. Since the patient is now clinically stable, the recommendation is to continue antibiotics until stability is achieved and for at least 5 days, which aligns with option C.",
    "reasoning_ground_truth": "Antibiotic therapy for pneumonia should be continued **until a validated measure of clinical stability has been achieved and for no less than 5 days**. Specific duration of treatment based on set number of days, without regard for stability, is not recommended, nor is discontinuing at discharge, unless at least 5 days of antibiotics have already been completed and the patient is clinically stable.",
    "context": "Recommendation. We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients. In switching from parenteral to oral antibiotics, either the same agent or the same drug class should be used.\nis associated with higher mortality and worse clinical outcomes (205\u2013207). Such failure should prompt assessment for a pathogen resistant to the current therapy and/or complications of pneumonia (e.g., empyema or lung abscess) or for an alternative source of infection and/or inflammatory response (208, 209). When assessment of clinical stability has been introduced into clinical practice, patients have shorter durations of antibiotic therapy without adverse impact on outcome (210). All\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nLonger courses of antibiotic therapy are recommended for 1) pneumonia e59  \ncomplicated by meningitis, endocarditis, and other deep-seated infection; or 2) infection with other, less-common pathogens not covered in these guidelines (e.g., Burkholderia pseudomallei, Mycobacterium tuberculosis or endemic fungi).",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 57-year-old male with a long history of heavy alcohol use presents with worsening jaundice, ascites, and new onset confusion. He is diagnosed with acute liver failure (ALF). The patient's family is concerned about the development of intracranial pressure (ICP). What intervention should the health team implement to manage elevated ICP in this situation?",
    "options": [
      "Initiate intravenous dexamethasone",
      "Administer intravenous mannitol or hypertonic saline.",
      "Reduce the amount of IV fluids to decrease fluid overload.",
      "Administer intravenous albumin to increase intravascular volume."
    ],
    "correct_answer_text": "Administer intravenous mannitol or hypertonic saline.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that patients with hyper-acute acute liver failure (ALF) and elevated ammonia levels are at increased risk for cerebral edema and intracranial hypertension (ICH). Invasive intracranial pressure monitoring is suggested for patients at high risk of ICH, and the management of elevated ICP typically involves interventions such as administering intravenous mannitol or hypertonic saline, which are known to help reduce intracranial pressure. The other options do not directly address the management of elevated ICP as effectively as option B.",
    "reasoning_ground_truth": "The use of **hypertonic saline or intravenous mannitol** is recommended to treat sustained surges in ICP. Steroids are not recommended for treatment of elevated ICP in ALF. The purpose of fluid bolus in these cases is to increase stroke volume and cardiac output rather than volume resuscitation.",
    "context": "Patients with hyper-acute ALF and elevated and sustained arterial ammonia levels (>150 mMol/l) may be at increased risk of cerebral edema and development of intra-cranial hypertension [177,178]. In this specific setting where there may be short-lived but current clinical practice adopted in many European liver units demonstrates the safety and feasibility of EN in ALF patients.  \nStrong consensus (100% agreement)  \nRecommendation 11\n[278] Wendon JA, Larsen FS. Intracranial pressure monitoring in acute liver failure. A procedure with clear indications. Hepatology 2006;44:504\u2013506.  \n[279] Bernuau J, Durand F. Intracranial pressure monitoring in patients with acute liver failure: a questionable invasive surveillance. Hepatology 2006;44:502\u2013504.  \n[280] Fortea JI, Banares R, Vaquero J. Intracranial pressure in acute liver failure: to bolt or not to bolt\u2014that is the question. Crit Care Med 2014;42:1304\u20131305.\n[219] Munoz SJ, Rajender Reddy K, Lee WAcute Liver Failure Study Group. The coagulopathy of acute liver failure and implications for intracranial pressure monitoring. Neurocrit Care 2008;9:103\u2013107.  \n[220] Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 2005;11:1581\u20131589.\nIn general, decisions on when to initiate nutrition support and which route to use are made in accordance with the recommendations for nutrition support in other intensive care unit (ICU) patient groups. Three subtypes of ALF can be classified according to their clinical course. In \u2018hyper-acute\u2019 liver failure the onset of hepatic encephalopathy (HE) occurs within seven days of the onset of jaundice and patients most often recover promptly with medical therapy alone or after transplantation or\nInvasive intracranial pressure monitoring should be considered in a highly selected subgroup of patients, who have progressed to grade 3 or 4 coma, are intubated and ventilated and deemed at high risk of ICH, based on the presence of more than one of the following variables: a) young patients with hyperacute or acute presentation, b) ammonia level over 150\u2013200 \u00b5mol/L that does not drop with initial treatment interventions (RRT and fluids), c) renal impairment and d) vasopressor support (>0.1",
    "ground_truth_context": "Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "is_correct": true
  },
  {
    "question": "A 60-year-old female with type 2 diabetes is being evaluated for chronic kidney disease (CKD). Her initial eGFR based on serum creatinine is 50 mL/min/1.73 m\u00b2. What is the next appropriate test for evaluation of her kidney function?",
    "options": [
      "Repeat serum creatinine measurement in 1 month",
      "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
      "24-hour urine collection for albumin",
      "Perform kidney biopsy"
    ],
    "correct_answer_text": "Measure cystatin C and calculate eGFR using both creatinine and cystatin C",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context specifies that for adults at risk for CKD, the recommended approach is to use creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (eGFRcr-cys). Since the patient is being evaluated for CKD and cystatin C is mentioned as a supportive test for greater accuracy, measuring cystatin C and calculating eGFR using both creatinine and cystatin C is the next appropriate step. Options A, C, and D do not align with the recommended evaluation approach outlined in the context.",
    "reasoning_ground_truth": "If eGFR based on creatinine is thought to be inaccurate or a more accurate assessment of GFR is needed, the next step is to measure cystatin C and calculate the **eGFR using both creatinine and cystatin C**. 24 hour urine collection and kidney biopsy are not used as the next step but are used for other specific reasons.  ",
    "context": "Practice Point 2.1.1: Assess albuminuria in adults, or albuminuria/proteinuria in children, and GFR at least annually in people with CKD.  \nPractice Point 2.1.2: Assess albuminuria and GFR more often for individuals at higher risk of CKD progression when measurement will impact therapeutic decisions.  \nPractice Point 2.1.3: For people with CKD, a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation.\nThe KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease recommended \u201cto report eGFRcr in adults using the 2009 CKD-EPI creatinine equation. An alternative creatinine-based GFR estimating equation is acceptable if it has been shown to improve accuracy of GFR estimates compared to the 2009 CKD-EPI creatinine equation.\u201d We are updating this recommendation to accommodate the availability of alternative equations that also have high levels of accuracy.\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]).\nRecommendation 1.1.2.1: In adults at risk for CKD, we recommend using creatinine-based estimated glomerular filtration rate (eGFRcr). If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (creatinine and cystatin C\u2013based estimated glomerular filtration rate [eGFRcr-cys]) (1B).\nIn this section, we describe the overall approach for the evaluation of GFR. As in the previous KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, the first method to evaluate GFR should be eGFRcr. If necessary for greater accuracy, the approach then recommends subsequent supportive tests from either the more accurate eGFRcr-cys or measurement of GFR using urinary or plasma clearance of exogenous filtration markers. In contrast to the previous",
    "ground_truth_context": "If eGFRcr is expected to be inaccurate, or if a more accurate assessment of GFR is needed for clinical decision-making, such as diagnosis or staging of chronic kidney disease or drug dosing, then, if available, cystatin C should be measured, and creatinine and cystatin C\u2013based estimated GFR (eGFRcr-cys) should be estimated.",
    "is_correct": true
  },
  {
    "question": "A 75-year-old male with acute bacterial rhinosinusitis (ABRS) symptoms for 10 days, including purulent nasal discharge, facial pain, and fever, reports no improvement with initial saline irrigation. He is also started on amoxicillin/clavulanate. When should the patient be reassessed?",
    "options": [
      "Reassess in 1 week if symptoms are persistent.",
      "Reassess immediately if symptoms worsen",
      "Reassess in 2 weeks, or sooner if needed.",
      "Reassess only if complications develop."
    ],
    "correct_answer_text": "Reassess in 1 week if symptoms are persistent.",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that a clinician should diagnose acute bacterial rhinosinusitis (ABRS) when symptoms persist without improvement for at least 10 days. Given that the patient has had symptoms for 10 days and is on treatment, it is appropriate to reassess in 1 week if symptoms are persistent, as this aligns with the management strategy for ABRS. Other options do not align with the recommended reassessment timeframe based on the context provided.",
    "reasoning_ground_truth": "Patients with ABRS should be reassessed **if symptoms persist after 7 days** on initial treatment, or if there is a worsening of symptoms.",
    "context": "|Acute bacterial rhinosinusitis (ABRS)|Acute rhinosinusitis that is caused by, or is presumed to be caused by, bacterial infection. A clinician should diagnose ABRS when: a. symptoms or signs of acute rhinosinusitis fail to improve within 10 days or more beyond the onset of upper respiratory symptoms, or b. symptoms or signs of acute rhinosinusitis worsen within 10 days after an initial improvement (double worsening)|\n|Recurrent acute rhinosinusitis|Four or more episodes per year of acute bacterial rhinosinusitis (ABRS) without signs or symptoms of rhinosinusitis between episodes: \u2022 each episode of ABRS should meet diagnostic criteria in Table 4.|\npresent 10 days or more beyond the onset of upper respiratory symptoms\u201d to \u201cA clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms.\u201d\nClinicians should distinguish presumed acute bacterial rhinosinusitis (ABRS) from acute rhinosinusitis caused by viral upper respiratory infections and noninfectious conditions. A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without\n- Extension of watchful waiting (without antibiotic therapy) as an initial management strategy to all patients with uncomplicated acute bacterial rhinosinusitis (ABRS) regardless of severity, not just patients with \u201cmild\u201d illness (prior guideline)\n- Change in recommendation from first-line antibiotic therapy for acute bacterial rhinosinusitis amoxicillin, with or without clavulanate, from amoxicillin alone (prior guideline)",
    "ground_truth_context": "Define realistic expectations regarding clinical response to initial management and to articulate clearly when reassessment of the patient is warranted",
    "is_correct": true
  },
  {
    "question": "A 35-year-old male in the hospital is experiencing a seizure. The seizure has lasted for 22 minutes and intravenous access has been established. He was treated with lorazepam at 5 minutes. What is the most appropriate next step in managing his status epilepticus?",
    "options": [
      "Repeat the intravenous lorazepam dose.",
      "Administer intravenous fosphenytoin.",
      "Administer intramuscular midazolam.",
      "Start a phenobarbital infusion."
    ],
    "correct_answer_text": "Administer intravenous fosphenytoin.",
    "correct_answer_idx": 1.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that in the study, a repeat dose of lorazepam could be given if the seizure continued after 4 minutes, with a maximum dose of 4 mg. Since the patient has been experiencing a seizure for 22 minutes and has already received lorazepam at 5 minutes, it is appropriate to repeat the intravenous lorazepam dose as the next step in managing his status epilepticus. Other options do not align with the immediate management protocol outlined in the context.",
    "reasoning_ground_truth": "When a seizure continues after initial benzodiazepine therapy, the next recommended step is to administer a second line agent, such as fosphenytoin, valproic acid, or levetiracetam. Repeating the intravenous lorazepam dose is not preferred as the seizure has exceeded the initial therapy window and a second line therapy should be initiated.",
    "context": "A second class I study in adults (older than 18 years) with status epilepticus was initiated outside the hospital by paramedics (23). In this 2001 study, patients were randomized to receive 2 mg IV lorazepam or 5 mg IV diazepam or IV placebo in the ambulance. The protocol allowed a repeat dose if the seizure continued after 4 minutes (for a maximum lorazepam dose of 4 mg and diazepam dose of 10 mg). For this study, status epilepticus was defined as continuous or repeated seizure for >5 minutes\nA 1983 class II study compared IV lorazepam 4 mg and IV diazepam 10 mg in adults with convulsive status epilepticus (defined as \u22653 GTC seizures in 1 hour or \u22652 in rapid succession), absence status epilepticus, or complex partial status epilepticus (25). The patients could receive a second dose of medication if the seizures continued after 10 minutes. For all patients, phenytoin was given after 30 minutes. A total of 70 patients were randomized to either lorazepam (n = 37) or diazepam (n = 33)\nas continuous or repeated seizure for >5 minutes without recovery of consciousness. Overall, 205 patients were randomized (lorazepam, n = 66; diazepam, n = 68; placebo, n = 71). The treatment was deemed successful if the status epilepticus had terminated at the time of arrival in the emergency department. Both lorazepam and diazepam were superior to placebo: lorazepam (59.1%) > placebo (21.1%) (OR, 4.8; 95% CI: 1.9\u201313.0) and diazepam (42.6%) > placebo (21.1%) (OR, 2.3; 95% CI: 1.0\u20135.9) (23).\n(22). Overt status epilepticus was defined as a continuous GTC seizure lasting 10 minutes or longer, or two or more GTC seizures without full recovery of consciousness. A treatment was successful if the status epilepticus stopped within 20 minutes after infusion started with no recurrence prior to 60 minutes. Overall, 570 patients were randomized to either lorazepam (n = 146), diazepam plus phenytoin (n = 146), phenobarbital (n = 133), or phenytoin (n = 145). Differential anticonvulsant\n25. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983;249:1452\u20131454.\n26. Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, Lampl Y. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 2008;118:296\u2013300.",
    "ground_truth_context": "Reasonable options for second-line therapy include fosphenytoin, valproic acid, and levetiracetam.",
    "is_correct": false
  },
  {
    "question": "A 65 year old patient with known cirrhosis and newly diagnosed hepatic encephalopathy is admitted to the hospital. She is stable and has a history of medication intolerance. Which is the preferred medication for hepatic encephalopathy?",
    "options": [
      "Lactulose",
      "Rifaximin",
      "Intravenous steroids",
      "Oral neomycin"
    ],
    "correct_answer_text": "Lactulose",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context provided discusses various studies on the treatment of hepatic encephalopathy, primarily focusing on branched-chain amino acids and their effectiveness. However, it does not mention lactulose, rifaximin, intravenous steroids, or oral neomycin directly. Given that lactulose is a well-established treatment for hepatic encephalopathy and is commonly used in clinical practice, it is the most appropriate choice for a patient with cirrhosis and hepatic encephalopathy, especially considering the patient's history of medication intolerance which may make other options less suitable.",
    "reasoning_ground_truth": "The preferred first line treatment for Hepatic encephalopathy is **Lactulose**. While Rifaximin may also be used, guidelines recommend starting with Lactulose. Intravenous steroids are not indicated in the management of HE. Oral neomycin is an alternative therapy but not first line. ",
    "context": "6. Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985;5(5):282e9.\n9. Vilstrup H, Gluud C, Hardt F, Kristensen M, Kohler O, Melgaard B, et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double-blind study of 65 patients with cirrhosis. J Hepatol 1990;10(3):291e6.\n10. Wahren J, Denis J, Desurmont P, Eriksson LS, Escoffier JM, Gauthier AP, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983;3(4):475e80.\n11. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian multicenter study group. J Hepatol 1990;11(1):92e101.\n4. Cerra FB, Cheung NK, Fischer JE, Kaplowitz N, Schiff ER, Dienstag JL, et al. Disease-specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double-blind, controlled trial. J Parenter Enteral Nutr 1985;9(3):288e95.\n5. Fiaccadori F. Branched-chain enriched amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital J Gastroenterol 1985;17:5e10.\n50. Van der Rijt CC, Schalm SW, Schat H, Foeken K, De Jong G. Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 1991;100(4):1114e8.\n51. Bresci G, Parisi G, Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. Eur J Med 1993;2(7):414e6.\n52. Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984;2(8401):493e5.",
    "ground_truth_context": "Continuous renal replacement therapy (RRT) is preferred over intermittent dialysis to avoid metabolic and hemodynamic fluctuations. Hypertonic saline or intravenous mannitol can be used to treat sustained surges in intracranial pressure (ICP). Steroids are not recommended for treating elevated ICP in ALF.",
    "is_correct": true
  },
  {
    "question": "A 50-year-old female with a diagnosis of primary open-angle glaucoma (POAG) has been treated with two different eye drop medications, but her intraocular pressure (IOP) is still not well controlled. What is the next step in her management?",
    "options": [
      "Consider laser trabeculoplasty",
      "Increase the dose of the current eye drops",
      "Add a third eye drop medication",
      "Refer for glaucoma surgery immediately"
    ],
    "correct_answer_text": "Consider laser trabeculoplasty",
    "correct_answer_idx": 0.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that if IOP is poorly controlled on several medications, glaucoma surgery may be indicated initially. However, it also suggests that laser therapy, such as laser trabeculoplasty, is a common next step before considering surgery. Since the patient has not achieved adequate IOP control with two medications, considering laser trabeculoplasty (Option A) aligns with the management strategies outlined in the context. Options B and C involve increasing or adding medications, which may not be the most effective next step given the patient's current situation. Option D suggests immediate referral for surgery, which is not indicated as the first step when other less invasive options, like laser therapy, are available.",
    "reasoning_ground_truth": "When medications do not adequately control IOP, **laser trabeculoplasty** is the next logical step to be considered before surgery is considered. While adding another eye drop medication is an option, it is not the preferred first step after initial treatment with two eye drop medications.",
    "context": "Patients with POAG who have visually significant cataracts have a range of options available. If IOP control is at target on one or two medications, cataract surgery alone may be adequate, with the additional benefit that it may lower IOP slightly. If IOP is poorly controlled on several medications or there is evidence of glaucomatous progression in a patient with a moderate cataract, glaucoma surgery may be indicated initially, with the plan to perform cataract surgery once IOP is adequately\nThe goals of managing patients with POAG are as follows:  \n- Control of IOP in the target range\n- Stable optic nerve/RNFL status\n- Stable visual fields  \nOphthalmologists can lower IOP with medications, laser therapy, or incisional surgery. Results from randomized controlled trials (summarized in Table 2) and other studies provide evidence that these treatments reduce IOP and decrease the rate and incidence of progressive POAG.8, 25, 70-75, 79, 80, 82, 306-319\nThe goals of managing patients with POAG are to control IOP in a target range and to prevent progressive visual field and optic nerve/RNFL damage in order to preserve visual function and quality of life. The initial glaucoma evaluation includes all components of the comprehensive adult medical evaluation focusing on those elements that specifically pertain to the diagnosis and management of POAG. Important diagnostic testing includes central corneal thickness measurement, visual field\nEstablished risk factors for primary open-angle glaucoma (POAG) include older age, African race or Latino/Hispanic ethnicity, elevated intraocular pressure (IOP), family history of glaucoma, low ocular perfusion pressure, type 2 diabetes mellitus, myopia, and thin central cornea.  \nPrimary open-angle glaucoma patients often have untreated IOP consistently within the normal range (i.e., normal tension glaucoma). Lowering pressure in these patients is beneficial.\nMedical therapy is presently the most common initial intervention to lower IOP (see Table 4 for an overview of options available). Prostaglandin analogs are the most frequently prescribed eye drops for lowering IOP in patients with glaucoma because they are most efficacious and well tolerated, and they need to be instilled only once daily.75, 326-328",
    "ground_truth_context": "Patients should receive proper professional support and referrals when their conditions fail to respond to treatment.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old male with rheumatoid arthritis (RA) is on methotrexate monotherapy, but is still having moderate disease activity. He is now being started on a biologic DMARD (bDMARD). What is the best way to approach his current methotrexate therapy?",
    "options": [
      "Discontinue methotrexate at the time of starting the bDMARD",
      "Reduce the dose of methotrexate while starting the bDMARD",
      "Continue methotrexate at the same dose when starting the bDMARD",
      "Stop methotrexate and start the bDMARD"
    ],
    "correct_answer_text": "Continue methotrexate at the same dose when starting the bDMARD",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that a treat-to-target approach is strongly recommended for patients who have not been previously treated with bDMARDs or tsDMARDs, which includes dose optimization of methotrexate and the addition of DMARDs when required. Since the patient is already on methotrexate monotherapy and is now being started on a bDMARD due to moderate disease activity, the best approach is to continue methotrexate at the same dose while adding the bDMARD, as this aligns with the recommendation for systematic monitoring and adjustment of treatment to minimize inflammation.",
    "reasoning_ground_truth": "According to guidelines, when adding a bDMARD to methotrexate therapy, the recommendation is to **continue methotrexate at the current dose**. Discontinuation or reducing the dose of methotrexate is not recommended at this time.",
    "context": "Methotrexate monotherapy is conditionally recommended over methotrexate plus a tumor necrosis factor (TNF) inhibitor for DMARD-naive patients with moderate-to-high disease activity. Methotrexate monotherapy is strongly preferred given the lack of proven benefit and additional risks and costs associated with the addition of a non\u2013TNF inhibitor bDMARD or tsDMARD in this patient population.\nMethotrexate monotherapy is strongly recommended over bDMARD or tsDMARD monotherapy for DMARD-naive patients with moderate-to-high disease activity. There is low-certainty evidence suggesting superiority of tocilizumab monotherapy (15) over methotrexate monotherapy and moderate-certainty evidence suggesting greater efficacy.\nMethotrexate is conditionally recommended over alternative DMARDs for the treatment of inflammatory arthritis for patients with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity.\nMethotrexate monotherapy is conditionally recommended over dual or triple csDMARD therapy for DMARD-naive patients with moderate-to-high disease activity. The recommendation favors methotrexate monotherapy because the higher burden of combination therapy (e.g., multiple medications, higher cost) outweighs the moderate-quality evidence suggesting greater improvements in disease activity associated with combination csDMARDs. The recommendation is conditional because some patients may choose\nA treat-to-target approach is strongly recommended over usual care for patients who have not been previously treated with bDMARDs or tsDMARDs. This recommendation applies to dose optimization of methotrexate and to the subsequent addition of DMARDs when required. The recommendation is strong despite low-certainty evidence because of the recognized importance of systematic monitoring and adjustment of treatment to minimize inflammation to prevent joint damage, as well as other long-term sequelae",
    "ground_truth_context": "Continuation of DMARDs at the current dose is preferred over dose reduction, which is preferred over gradual discontinuation, which is preferred over abrupt discontinuation.",
    "is_correct": true
  },
  {
    "question": "A 28-year-old male presents to the clinic with concern for possible gonorrhea. He reports a recent unprotected sexual encounter.  What is the preferred initial treatment if he is diagnosed with gonorrhea?",
    "options": [
      "Oral azithromycin 1 gram single dose",
      "Oral doxycycline 100mg twice daily for 7 days",
      "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
      "Oral ciprofloxacin 500 mg twice daily for 3 days"
    ],
    "correct_answer_text": "Intramuscular ceftriaxone 500 mg and oral azithromycin 1 gram single dose",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that updated treatment recommendations for gonorrhea include dual therapy, particularly in settings where local resistance data are not available. The preferred initial treatment mentioned aligns with the dual therapy approach, which consists of intramuscular ceftriaxone and oral azithromycin. Other options either do not reflect the current guidelines or involve treatments that have been withdrawn due to resistance issues.",
    "reasoning_ground_truth": "The recommended initial treatment for gonorrhea is a single dose of **intramuscular ceftriaxone along with a single dose of oral azithromycin**.",
    "context": "Updated treatment recommendations based on the most recent evidence are included for the most important common conditions caused by N. gonorrhoeae. Recommendations were not updated for rare conditions and other conditions for which no new information became available since the 2003 WHO STI guidelines were issued. Treatment recommendations for the following conditions caused by N. gonorrhoeae are included in these guidelines:  \n- genital and anorectal infections\n- oropharyngeal infections\nIn settings where local resistance data are not available, the WHO STI guideline suggests dual therapy over single therapy for people with genital or anorectal gonorrhoea.\nGonococcal treatment guidelines need to be updated in response to the changing antimicrobial susceptibility patterns of N. gonorrhoeae. Increased resistance to most antibiotics used to treat gonococcal infections has been reported worldwide, raising concerns about the eventual development of untreatable gonococcal infections with serious sexual and reproductive health consequences (6). The previous WHO Guidelines for the management of sexually transmitted infections, published in 2003 (7),\nKey populations are at increased risk of transmitting and acquiring STIs, including N. gonorrhoeae. It is critical to increase access to STI services including treatment for specific STIs for key populations and people living with HIV. The following WHO guidelines provide recommendations and guidance on increasing access to and delivering STI services for key populations.\ntransmitted infections, published in 2003 (7), include ciprofloxacin as a first-line treatment for gonorrhoea, even though high levels of resistance to quinolones are reported in most countries and these medicines have been withdrawn from all international guidelines. Decreased susceptibility to the extended spectrum (third-generation) cephalosporins, another recommended first-line treatment in the 2003 guidelines, is becoming more widespread and several countries have reported treatment",
    "ground_truth_context": "Treatments for people with treatment failure of N. gonorrhoeae (genital or oropharyngeal). Included studies: randomized and non-randomized studies",
    "is_correct": true
  },
  {
    "question": "A 70-year-old patient is admitted to the hospital for an acute medical illness. They have limited mobility during the admission. What is the preferred initial method of VTE prophylaxis?",
    "options": [
      "Mechanical prophylaxis with graduated compression stockings",
      "Mechanical prophylaxis with intermittent pneumatic compression",
      "Pharmacological prophylaxis with LMWH or UFH",
      "No prophylaxis is necessary due to limited VTE risk."
    ],
    "correct_answer_text": "Pharmacological prophylaxis with LMWH or UFH",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context indicates that for acutely or critically ill medical patients, the ASH guideline panel suggests using mechanical VTE prophylaxis methods such as pneumatic compression devices or graduated compression stockings. Since the patient is admitted for an acute medical illness and has limited mobility, the preferred initial method of VTE prophylaxis would be mechanical prophylaxis with graduated compression stockings, as it aligns with the recommendations provided in the context.",
    "reasoning_ground_truth": "For acutely ill medical patients, guidelines recommend **pharmacologic prophylaxis with a low molecular weight heparin (LMWH) or unfractionated heparin (UFH)**. Mechanical prophylaxis can be used in certain situations, but is not the preferred initial method",
    "context": "Should VTE prophylaxis be used in medical outpatients with minor provoking factors for VTE (eg, immobility, minor injury, illness/infection)?\nprophylaxis for persons without risk factors. For long-distance travelers at increased risk for VTE, the ACCP recommended 15- to 30-mm Hg below-knee graduated compression stockings, frequent ambulation, calf muscle exercise, or sitting in an aisle seat. They recommended against the use of aspirin or anticoagulants. The ASH panel recommended LMWH or graduated compression stockings and the use of aspirin if these were not feasible or available.\nShould mechanical VTE prophylaxis vs pharmacological VTE prophylaxis be used in acutely or critically ill medical patients?  \nShould mechanical VTE prophylaxis vs no VTE prophylaxis be used in acutely or critically ill medical patients?  \nShould mechanical combined with pharmacological vs mechanical VTE prophylaxis alone be used in acutely or critically ill medical patients?\nIn acutely or critically ill medical patients who are receiving mechanical VTE prophylaxis, the ASH guideline panel suggests using pneumatic compression devices or graduated compression stockings for VTE prophylaxis (conditional recommendation, very low certainty in the evidence of effects \u00c5\u25ef\u25ef\u25ef).\nIn acutely or critically ill medical patients who are not receiving pharmacological VTE prophylaxis, the ASH guideline panel suggests using pneumatic compression devices or graduated compression stockings for VTE prophylaxis (conditional recommendation, very low certainty in the evidence of effects \u00c5\u25ef\u25ef\u25ef).",
    "ground_truth_context": "LMWH vs UFH in acutely ill medical patients. Summary of the evidence. We found 8 systematic reviews51,52,54,58,59,63,65,67 that addressed this question and included 11 RCTs.",
    "is_correct": false
  },
  {
    "question": "A 54 year-old male is admitted to the hospital with community-acquired pneumonia (CAP). His blood cultures are negative, and his symptoms are improving after 3 days of intravenous antibiotics. How long should he continue antibiotic therapy?",
    "options": [
      "Continue intravenous antibiotics for 7 days",
      "Switch to oral antibiotics for 7 days",
      "Continue intravenous antibiotics until clinical stability and then for 2 additional days",
      "Continue antibiotics until clinical stability is achieved and for at least 5 days"
    ],
    "correct_answer_text": "Continue antibiotics until clinical stability is achieved and for at least 5 days",
    "correct_answer_idx": 3.0,
    "model_answer": "D",
    "model_answer_idx": 3,
    "model_reasoning": "The context states that antibiotic therapy should be continued until the patient achieves clinical stability and for no less than a total of 5 days. Since the patient has shown improvement after 3 days of intravenous antibiotics, he should continue the treatment until he reaches clinical stability and for at least 5 days total, aligning with the recommendation provided in the context.",
    "reasoning_ground_truth": "Antibiotic therapy for CAP should be continued until the patient achieves **clinical stability and for at least 5 days**. The route of administration of the antibiotic should be based on the patient\u2019s ability to tolerate oral intake.",
    "context": "We acknowledge that most studies in support of 5 days of antibiotic therapy include patients without severe CAP, but we believe these results apply to patients with severe CAP and without infectious complications. We believe that the duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines (166).\nIn Outpatient and Inpatient Adults with CAP Who Are Improving, What Is the Appropriate Duration of Antibiotic Treatment?\nSummary of the evidence. A small number of randomized trials address the appropriate duration of antibiotic therapy in CAP, and randomized placebo-controlled trials of high quality are mostly limited to the inpatient setting. In these trials, no difference was observed between 5 additional days of oral amoxicillin compared with placebo in patients who had clinically improved on 3 days of intravenous amoxicillin (194), or between 2 days of intravenous cefuroxime followed by 5 days versus 8 days\nRecommendation. We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).\nAs recent data supporting antibiotic administration for ,5 days are scant, on a risk\u2013benefit basis we recommend treating for a minimum of 5 days, even if the patient has reached clinical stability before 5 days. As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients. In switching from parenteral to oral antibiotics, either the same agent or the same drug class should be used.",
    "ground_truth_context": "Antibiotic therapy duration should be guided by a validated measure of clinical stability and should be continued until stability is achieved and for no less than 5 days.",
    "is_correct": true
  },
  {
    "question": "A 45-year-old female with chronic rhinosinusitis (CRS) presents with persistent nasal congestion and facial pain despite using saline nasal irrigation and topical corticosteroids. She reports no history of allergies. What is the next most appropriate step in her management?",
    "options": [
      "Prescribe a course of oral antibiotics.",
      "Recommend allergy testing and consider immunotherapy.",
      "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
      "Obtain a CT scan of the sinuses to assess for anatomical abnormalities."
    ],
    "correct_answer_text": "Perform nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation.",
    "correct_answer_idx": 2,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of confirming the presence or absence of nasal polyps in patients with chronic rhinosinusitis (CRS) as part of the management process. Since the patient has persistent symptoms despite treatment, performing nasal endoscopy to assess for polyps and obtain objective evidence of sinonasal inflammation aligns with the recommended management steps for CRS. Options A, B, and D do not directly address the immediate need to evaluate for polyps or inflammation as indicated in the context.",
    "reasoning_ground_truth": "The patient has persistent CRS despite initial management, it is important to obtain objective evidence of sinonasal inflammation, and evaluate for nasal polyps by nasal endoscopy. Antibiotics are not a primary treatment for CRS. Allergy testing may be considered, but an objective confirmation of CRS should be prioritized. CT scan is an option for objective documentation but nasal endoscopy is a more appropriate first-line diagnostic step.",
    "context": "- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\nCRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\noption by 7 days after diagnosis or worsens during the initial management; (4) distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation,\nSymptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly sensitive for diagnosing CRS, but symptom-based criteria alone are relatively nonspecific. Diagnosing CRS requires that inflammation be documented (polyps, edema, or purulent mucus) in addition to persistent\n|10. CRS with polyps|The clinician should confirm the presence or absence of nasal polyps in a patient with CRS.|\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "is_correct": true
  },
  {
    "question": "A 52-year-old male, post-stent placement for stable ischemic heart disease (SIHD) 6 months ago, is scheduled for an elective cholecystectomy. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. What is the most appropriate perioperative management of his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel throughout the perioperative period.",
      "Discontinue both aspirin and clopidogrel 5 days before surgery.",
      "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
      "Discontinue aspirin and continue clopidogrel throughout the perioperative period."
    ],
    "correct_answer_text": "Continue aspirin and discontinue clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context specifies that in patients treated with DAPT after coronary stent implantation, it is recommended to continue aspirin if possible and to restart the P2Y12 inhibitor (in this case, clopidogrel) as soon as possible after surgery. Since the patient is 6 months post-stent placement for SIHD and requires surgery, the most appropriate management is to continue aspirin and discontinue clopidogrel 5 days prior to surgery, aligning with the recommendation to manage antiplatelet therapy during surgical procedures.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective surgery, it is generally recommended to continue aspirin and discontinue the P2Y12 inhibitor (in this case, clopidogrel) 5 days prior to surgery to reduce the risk of bleeding. Stopping both medications increases the risk of thrombotic events. Continuing both medications increases bleeding risk",
    "context": "opinion. If a P2Y12 inhibitor has been held before a surgical procedure, therapy is restarted as soon as possible, given the substantial thrombotic hazard associated with lack of platelet inhibition early after surgery in patients with recent stent implantation. Although several small studies have used intravenous antiplatelet agents as a means of \u201cbridging\u201d in patients requiring temporary discontinuation of DAPT before surgery, there is no convincing clinical evidence demonstrating the efficacy\nAlthough there are several potential combinations of antiplatelet therapy, the term and acronym DAPT has been used to specifically refer to combination antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) and will be used similarly in this focused update. Recommendations in this focused update on duration of DAPT, aspirin dosing in patients treated with DAPT, and timing of elective noncardiac surgery in patients treated with percutaneous\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|B-R|In patients with ACS who are managed with medical therapy alone (without revascularization or fibrinolytic therapy) and treated with DAPT, P2Y12 inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months (52,71,140,141).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as possible after surgery.|\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|A|In patients with SIHD treated with DAPT after BMS implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for a minimum of 1 month (94,95).|\n|I|B-RSR|In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "question": "A 68-year-old female presents with a 3-day history of fever, cough, and purulent nasal discharge. She has a history of well-controlled asthma. She reports her symptoms began after a recent cold and is concerned about a sinus infection. What is the most appropriate next step in her management?",
    "options": [
      "Start empiric antibiotics immediately",
      "Obtain a sinus CT to determine extent of infection.",
      "Recommend symptomatic relief and observe her symptoms for 7 days.",
      "Prescribe oral corticosteroids to manage inflammation."
    ],
    "correct_answer_text": "Recommend symptomatic relief and observe her symptoms for 7 days.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that the guideline emphasizes assessing patients with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (ARS) for multiple chronic conditions, such as asthma, which the patient has. It suggests that management should include observing symptoms for a period before taking further action, particularly if the symptoms are not severe. Therefore, recommending symptomatic relief and observing her symptoms for 7 days aligns with the guideline's approach to managing similar cases.",
    "reasoning_ground_truth": "The patient has symptoms for 3 days, which is not long enough to diagnose ABRS. Given that her symptoms developed after a cold, it is likely a viral rhinosinusitis (VRS), symptomatic relief is the best option. Antibiotics are not indicated at this time, nor are CT scans or oral corticosteroids. It would be appropriate to reassess if symptoms worsen.",
    "context": "The guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic nonallergic rhinitis, vasomotor rhinitis, invasive fungal rhinosinusitis, allergic fungal rhinosinusitis, vascular headaches, and migraines. Similarly, the guideline will not consider management of rhinosinusitis in patients with the following modifying factors but will discuss the\nThe guideline is intended for all clinicians who are likely to diagnose and manage adults with rhinosinusitis and applies to any setting in which an adult with rhinosinusitis would be identified, monitored, or managed. This guideline, however, does not apply to patients younger than 18 years or to patients of any age with complicated rhinosinusitis.\nand guide management, which include radiography, nasal endoscopy, computed tomography, and testing for allergy and immune function. Emphasis was also placed on identifying multiple chronic conditions that would modify management of rhinosinusitis, including asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.\noption by 7 days after diagnosis or worsens during the initial management; (4) distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation,\n- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents",
    "ground_truth_context": "In contrast to the version of this statement in the original sinusitis guideline,1 we changed the diagnostic criteria to include not just the persistence of signs and symptoms beyond 10 days but failure to improve in 10 days, for greater specificity in distinguishing presumed bacterial infection for persistent, but resolving, viral illness. Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old male with a history of a myocardial infarction (MI) one year ago, treated with a drug-eluting stent, is currently on aspirin and clopidogrel. He has been free of any cardiac events since the procedure. Based on current guidelines, what is the recommended duration of dual antiplatelet therapy (DAPT)?",
    "options": [
      "Continue DAPT indefinitely.",
      "Continue DAPT for an additional 6 months.",
      "Discontinue clopidogrel and continue aspirin.",
      "Discontinue both aspirin and clopidogrel."
    ],
    "correct_answer_text": "Discontinue clopidogrel and continue aspirin.",
    "correct_answer_idx": 2.0,
    "model_answer": "A",
    "model_answer_idx": 0,
    "model_reasoning": "The context states that \"Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease.\" Additionally, it mentions that the duration of DAPT can vary, but in the absence of significant bleeding or ischemic events, the benefit/risk ratio may favor prolonged DAPT for patients with a high DAPT score. Since the patient has been free of any cardiac events since the procedure and has a history of MI treated with a drug-eluting stent, the recommendation aligns with continuing DAPT indefinitely.",
    "reasoning_ground_truth": "For patients with a history of MI treated with a drug-eluting stent who are beyond one year without any cardiac events, they are considered to have stable ischemic heart disease. They can discontinue the P2Y12 inhibitor, (clopidogrel) and continue with single antiplatelet therapy, usually aspirin.",
    "context": "The scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention\u201d (9), \u201c2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery\u201d (10), \u201c2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients\nColors correspond to Class of Recommendation in Table 1. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *Duration of DAPT therapy can vary from as little as 4 weeks to >12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non\u2013ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention;\nA new risk score (the \u201cDAPT score\u201d), derived from the Dual Antiplatelet Therapy study, may be useful for decisions about whether to continue (prolong or extend) DAPT in patients treated with coronary stent implantation. Analysis of study data suggests that in patients treated for 1 year with DAPT without significant bleeding or ischemic events, the benefit/risk ratio with prolonged DAPT may be favorable for those with a high DAPT score ($2) because prolonged DAPT reduces net (ischemic plus\nOverriding concepts and relevant recommendations for DAPT and duration of therapy are summarized in Table 3. Intensification of antiplatelet therapy, with the addition of a P2Y12 inhibitor to aspirin mono-therapy, necessitates a fundamental tradeoff between decreasing ischemic risk and increasing bleeding risk (40,41,50\u201352). Similarly, longer compared with shorter duration of DAPT generally results in decreased ischemic risk at the expense of increased bleeding risk (16,24,28,30,46). Use of more\nPatients in the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin\u2014Thrombolysis In Myocardial Infarction 54) trial were randomized 1 to 3 years after MI with additional high-risk features to either DAPT (with ticagrelor 60 mg or 90 mg twice daily) or continued aspirin monotherapy (28). After a mean of 33 months of therapy, DAPT, when compared with aspirin monotherapy, resulted in a 1.2% to 1.3%",
    "ground_truth_context": "For purposes of this focused update, patients with a history of acute coronary syndrome (ACS) >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to stable ischemic heart disease (SIHD) and are addressed in the section on SIHD.",
    "is_correct": false
  },
  {
    "question": "A 28-year-old female presents with a 2-day history of nasal congestion, clear nasal discharge, and mild facial pressure. She denies fever or purulent discharge. What is the most appropriate initial management?",
    "options": [
      "Prescribe an antibiotic to prevent a bacterial infection.",
      "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
      "Order a sinus CT scan to assess the extent of the sinus congestion.",
      "Prescribe a short course of oral corticosteroids."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants and nasal saline irrigation for symptomatic relief.",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The context indicates that for patients with symptoms like nasal congestion and clear nasal discharge, symptomatic relief is recommended. The patient in the scenario has mild symptoms without fever or purulent discharge, which aligns with the guideline's suggestion to recommend analgesics, decongestants, and nasal saline irrigation for symptomatic relief. Options A, C, and D are not supported by the context for this presentation.",
    "reasoning_ground_truth": "The patient's symptoms are consistent with a viral rhinosinusitis (VRS). Antibiotics are not indicated for viral infections. A sinus CT scan is not necessary given the non-severe nature of her symptoms. Oral corticosteroids are not appropriate for the typical treatment of a viral rhinosinusitis. Symptomatic relief with analgesics, decongestants, and nasal saline irrigation is the most appropriate initial strategy.",
    "context": "The guideline will not consider management of the following clinical presentations, although differential diagnosis for these conditions and bacterial rhinosinusitis will be discussed: allergic rhinitis, eosinophilic nonallergic rhinitis, vasomotor rhinitis, invasive fungal rhinosinusitis, allergic fungal rhinosinusitis, vascular headaches, and migraines. Similarly, the guideline will not consider management of rhinosinusitis in patients with the following modifying factors but will discuss the\nAnalgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the use of nasal saline in both physiologic and hypertonic concentrations.\n|Yes|Complication present?|No|\n|Recommend symptomatic relief for ABRS|Confirm the presence or absence of nasal polyps|KAS 3|\n|Manage complication and ABRS|KAS 4|Table 6|\n|Offer watchful waiting* OR prescribe antibiotic based on shared decision-making|*requires assurance of follow-up|KAS 8|\n|Decision to proceed with watchful waiting*|Decision to proceed with initial antibiotic therapy|KAS 5|\nin children from the American Academy of Pediatrics considered 3 or more days of concurrent high fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset or has high fever (>39\u00b0C or 102\u00b0F) and purulent discharge or facial pain lasting at least 3 to 4 consecutive\noption by 7 days after diagnosis or worsens during the initial management; (4) distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation,",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 65-year-old male with chronic rhinosinusitis (CRS) and nasal polyps has been using nasal saline irrigation and topical corticosteroids with minimal improvement. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10-day course of oral antibiotics",
      "Order an allergy skin test to evaluate for allergic rhinitis",
      "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
      "Continue current therapy with close follow up."
    ],
    "correct_answer_text": "Confirm the presence of sinonasal inflammation and consider a referral to an otolaryngologist.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of confirming the presence or absence of nasal polyps in patients with chronic rhinosinusitis (CRS) and suggests that clinicians should assess for multiple chronic conditions that could modify management. Given that the patient has nasal polyps and has had minimal improvement with current therapies, the next appropriate step is to confirm sinonasal inflammation and consider a referral to an otolaryngologist for further evaluation and management. Options A, B, and D do not align with the recommended actions in the context provided.",
    "reasoning_ground_truth": "Given his persistent symptoms despite initial therapy, it is important to confirm the diagnosis of CRS, and referral may be beneficial to assess other management strategies such as surgery. Oral antibiotics are not effective for CRS. Allergy testing can be considered, but the next priority is to confirm the diagnosis and further evaluate other treatment strategies",
    "context": "- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\n|10. CRS with polyps|The clinician should confirm the presence or absence of nasal polyps in a patient with CRS.|\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nCRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\noption by 7 days after diagnosis or worsens during the initial management; (4) distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation,\na new algorithm to clarify action statement relationships, expanded opportunities for watchful waiting (without antibiotic therapy) as initial therapy of acute bacterial rhinosinusitis (ABRS), and 3 new recommendations for managing chronic rhinosinusitis (CRS).",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Clinicians should confirm the presence or absence of nasal polyps in a patient with CRS.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old male with stable ischemic heart disease (SIHD) underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 3 months ago. He is currently on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel. He is now scheduled for a colonoscopy. What is the most appropriate perioperative management?",
    "options": [
      "Continue both aspirin and clopidogrel during the colonoscopy",
      "Stop both aspirin and clopidogrel 5 days prior to the colonoscopy",
      "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
      "Stop aspirin and continue clopidogrel during the colonoscopy"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days before the colonoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that aspirin therapy is almost always continued indefinitely in patients with coronary artery disease (CAD), while clopidogrel is the only P2Y12 inhibitor studied in patients with stable ischemic heart disease (SIHD) undergoing PCI. Given the high bleeding risk associated with colonoscopy, it is generally recommended to continue aspirin and stop clopidogrel prior to procedures to minimize bleeding risk while maintaining some level of antiplatelet protection. Therefore, option C, which suggests continuing aspirin and stopping clopidogrel 5 days before the colonoscopy, aligns with the recommendations for managing patients on DAPT in this scenario.",
    "reasoning_ground_truth": "For patients with SIHD undergoing elective procedures, guidelines recommend continuing aspirin and discontinuing the P2Y12 inhibitor, (clopidogrel) 5 days before the procedure to reduce bleeding risk while maintaining some protection against thrombotic events. Stopping both medications can increase risk of thrombotic events. Continuing both medications increases bleeding risk during the procedure",
    "context": "surgery in patients treated with percutaneous coronary intervention (PCI) and DAPT supersede prior corresponding recommendations in the 6 relevant guidelines. These recommendations for duration of DAPT apply to newer-generation stents and, in general, only to those not treated with oral anticoagulant therapy.\nColors correspond to Class of Recommendation in Table 1. Arrows at the bottom of the figure denote that the optimal duration of prolonged DAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. *High bleeding risk denotes those who have or develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy) or are at\nColors correspond to Class of Recommendation in Table 1. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with CAD. Patients with a history of ACS >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to SIHD. In patients treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention\u201d (9), \u201c2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery\u201d (10), \u201c2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients\nColors correspond to Class of Recommendation in Table 1. Patients with a history of ACS >1 year prior who have since remained free of recurrent ACS are considered to have transitioned to SIHD. Arrows at the bottom of the figure denote that the optimal duration of prolonged DAPT is not established. Clopidogrel is the only currently used P2Y12 inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued indefinitely in patients with coronary artery disease. 5",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "question": "A 30-year-old patient presents with a 14-day history of persistent nasal congestion, facial pressure, and purulent nasal discharge. The patient has no fever, and their symptoms started after a cold. Based on these symptoms, what is the appropriate diagnosis?",
    "options": [
      "Viral rhinosinusitis (VRS).",
      "Acute bacterial rhinosinusitis (ABRS).",
      "Allergic rhinitis.",
      "Migraine headache."
    ],
    "correct_answer_text": "Acute bacterial rhinosinusitis (ABRS).",
    "correct_answer_idx": 1.0,
    "model_answer": "B",
    "model_answer_idx": 1,
    "model_reasoning": "The patient presents with a 14-day history of persistent nasal congestion, facial pressure, and purulent nasal discharge. According to the context, acute bacterial rhinosinusitis (ABRS) is diagnosed when there is up to 4 weeks of purulent nasal drainage accompanied by nasal obstruction and facial pain-pressure-fullness. The presence of purulent nasal discharge indicates a bacterial infection rather than a viral one, which aligns with the criteria for ABRS. Therefore, the appropriate diagnosis is ABRS.",
    "reasoning_ground_truth": "The patient's symptoms of persistent nasal congestion, facial pressure, and purulent nasal discharge lasting over 10 days after a cold are highly suggestive of acute bacterial rhinosinusitis (ABRS). While VRS may present with similar symptoms, they typically resolve within 10 days. Allergic rhinitis and migraines do not typically present with purulent nasal discharge.",
    "context": "Symptoms of CRS vary in severity and prevalence. Nasal obstruction is most common (81%-95%) followed by facial congestion-pressure-fullness (70%-85%), discolored nasal discharge (51%-83%) and hyposmia (61%-69%). The presence of 2 or more signs or symptoms persisting beyond 12 weeks is highly sensitive for diagnosing CRS, but symptom-based criteria alone are relatively nonspecific. Diagnosing CRS requires that inflammation be documented (polyps, edema, or purulent mucus) in addition to persistent\nAcute rhinosinusitis is diagnosed when a patient presents with up to 4 weeks of purulent (not clear) nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both (Table 4). Nasal obstruction without purulent nasal drainage is not consistent with ARS and is beyond the scope of this guideline. Similarly, facial pain without purulent nasal drainage is not consistent with ARS, even though many patients present with a history of self-reported or physician-diagnosed \u201csinus\u201d\n|Acute rhinosinusitis (ARS)|Up to 4 weeks of purulent nasal drainage (anterior, posterior, or both) accompanied by nasal obstruction, facial pain-pressure-fullness, or both: Purulent nasal discharge is cloudy or colored, in contrast to the clear secretions that typically accompany viral upper respiratory infection, and may be reported by the patient or observed on physical examination. Nasal obstruction may be reported by the patient as nasal obstruction, congestion, blockage, or stuffiness, or\n|Chronic rhinosinusitis|Twelve weeks or longer of two or more of the following signs and symptoms: \u2022 mucopurulent drainage (anterior, posterior, or both), \u2022 nasal obstruction (congestion), \u2022 facial pain-pressure-fullness, or \u2022 decreased sense of smell. AND inflammation is documented by one or more of the following findings: \u2022 purulent (not clear) mucus or edema in the middle meatus or anterior ethmoid region, \u2022 polyps in nasal cavity or the middle meatus, and/or \u2022 radiographic imaging showing\nClinicians should confirm the diagnosis of ABRS by applying the diagnostic criteria in Table 4. If the patient does not have the symptom cluster of \u201cup to 4 weeks purulent nasal drainage . . . accompanied by nasal obstruction, facial pain-pressure-fullness, or both\u201d but instead has individual symptoms, alternate diagnoses should be explored. Migraines, tension headaches, cluster headaches, and temporomandibular joint disorder are common causes of facial pain that can be mistaken for ABRS.",
    "ground_truth_context": "A clinician should diagnose ABRS when (a) symptoms or signs of acute rhinosinusitis (purulent nasal drainage accompanied by nasal obstruction, facial pain-pressure-fullness, or both) persist without evidence of improvement for at least 10 days beyond the onset of upper respiratory symptoms, or (b) symptoms or signs of ARS worsen within 10 days after an initial improvement (double worsening).",
    "is_correct": true
  },
  {
    "question": "A 48-year-old male is diagnosed with chronic rhinosinusitis (CRS) based on his symptoms. To confirm the diagnosis, the clinician should obtain objective documentation of sinonasal inflammation. Which of the following is most appropriate to perform to confirm sinonasal inflammation?",
    "options": [
      "Allergy skin test.",
      "Sinus radiography.",
      "Anterior rhinoscopy or nasal endoscopy.",
      "Blood test for infection."
    ],
    "correct_answer_text": "Anterior rhinoscopy or nasal endoscopy.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context explicitly states that to confirm a clinical diagnosis of chronic rhinosinusitis (CRS), objective documentation of sinonasal inflammation is required, which can be accomplished using anterior rhinoscopy or nasal endoscopy. This directly supports option C as the most appropriate method for confirming sinonasal inflammation. Options A, B, and D do not align with the context's emphasis on the need for direct visualization or specific imaging techniques for this purpose.",
    "reasoning_ground_truth": "To confirm a diagnosis of CRS, objective documentation of sinonasal inflammation is required. This can be achieved through direct visualization using anterior rhinoscopy or nasal endoscopy. While a CT scan is an option, it is usually not the first step. Allergy testing and blood tests for infection are not appropriate methods for confirming sinonasal inflammation.",
    "context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. Strong recommendation based on cross-sectional studies with a preponderance of benefit over harm.\nThe purpose of this statement is to strongly emphasize that a diagnosis of CRS cannot be based on signs and symptoms alone but also requires objective evidence of sinonasal inflammation (Table 8). Requiring objective signs of inflammation increases diagnostic accuracy for CRS and serves to limit overdiagnosis. Moreover, objective confirmation of inflammation will prevent unnecessary tests and interventions for individuals with self-reported sinonasal symptoms that can be readily mistaken for\nThe update group made strong recommendations that clinicians (1) should distinguish presumed ABRS from acute rhinosinusitis (ARS) caused by viral upper respiratory infections and noninfectious conditions and (2) should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography. The update group made recommendations that clinicians (1) should either offer watchful waiting\n|7A. Diagnosis of CRS or recurrent ARS|Clinicians should distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms.|\n|7B. Objective confirmation of a diagnosis of CRS|The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.|\nObjective confirmation of sinonasal inflammation may be made by direct visualization or by CT scanning. Direct visualization is best accomplished with nasal endoscopy, but in some patients, anterior rhinoscopy using an otoscope or nasal speculum may suffice. An important part of direct visualization is identification of nasal polyps, as that will lead the clinician to rule out neoplasm in unilateral polyps, as well as suggest slightly different treatment stratagems for bilateral polyps. In the",
    "ground_truth_context": "The clinician should confirm a clinical diagnosis of CRS with objective documentation of sinonasal inflammation, which may be accomplished using anterior rhinoscopy, nasal endoscopy, or computed tomography.",
    "is_correct": true
  },
  {
    "question": "A 32-year-old male presents with a 5-day history of nasal congestion, facial pain, and clear nasal discharge following a cold. He denies fever or purulent discharge. What is the most appropriate initial treatment approach?",
    "options": [
      "Start empiric antibiotics for bacterial sinusitis.",
      "Prescribe oral corticosteroids to reduce inflammation.",
      "Recommend analgesics, decongestants, and nasal saline irrigation.",
      "Order a sinus CT scan to determine the severity of the infection."
    ],
    "correct_answer_text": "Recommend analgesics, decongestants, and nasal saline irrigation.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context indicates that adjunctive treatments for rhinosinusitis may aid in symptomatic relief and includes analgesics, decongestants, and saline irrigation as options. The patient presents with nasal congestion and facial pain but does not have fever or purulent discharge, which suggests a non-bacterial cause. Therefore, the most appropriate initial treatment approach is to recommend analgesics, decongestants, and nasal saline irrigation (Option C). Options A, B, and D are not supported by the context for this specific case.",
    "reasoning_ground_truth": "The patient's symptoms are indicative of a viral rhinosinusitis (VRS). Antibiotics are not indicated for a viral cause. Oral corticosteroids are not an initial therapy. A CT scan is not indicated. Symptomatic relief is the most appropriate first step",
    "context": "Analgesics or antipyretic drugs (acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory agents) may be given for pain or fever. Nasal saline may be palliative and cleansing with low risk of adverse reactions. A Cochrane review reported minor improvements in nasal symptom scores with the use of nasal saline in both physiologic and hypertonic concentrations.\nhave been used to treat nasal congestion associated with the common cold for many years.103-107 There are no RCTs that specifically study the efficacy of decongestants for ABRS, but 2 small studies have shown that xylometazoline nasal spray reduces congestion of sinus and nasal mucosa on imaging studies65,108 and is superior to a single orally administered dose of pseudoephedrine.108 Another small, nonrandomized study showed improved outcomes when xylometazoline spray was added to antibiotics\na new algorithm to clarify action statement relationships, expanded opportunities for watchful waiting (without antibiotic therapy) as initial therapy of acute bacterial rhinosinusitis (ABRS), and 3 new recommendations for managing chronic rhinosinusitis (CRS).\nAdjunctive treatments for rhinosinusitis that may aid in symptomatic relief include analgesics, decongestants (\u03b1-adrenergic), corticosteroids, saline irrigation, and mucolytics. None of these products has been specifically approved by the FDA for use in acute rhinosinusitis (as of March 2014), and only some have data from controlled clinical studies supporting this use. Moreover, existing trials often include cointerventions and a heterogeneous population of patients with viral, recurrent\nin children from the American Academy of Pediatrics considered 3 or more days of concurrent high fever and purulent nasal discharge as a \u201csevere\u201d presentation of ABRS that warrants antibiotic therapy. Similarly, the Infectious Disease Society of America guideline on ABRS recommended that the clinician consider a diagnosis of ABRS if the patient presented with severe symptoms at the onset or has high fever (>39\u00b0C or 102\u00b0F) and purulent discharge or facial pain lasting at least 3 to 4 consecutive",
    "ground_truth_context": "Clinicians may recommend analgesics, topical intranasal steroids, and/or nasal saline irrigation for symptomatic relief of VRS.",
    "is_correct": true
  },
  {
    "question": "A 55-year-old female with chronic rhinosinusitis (CRS) and nasal polyps has had minimal improvement with topical corticosteroids and saline irrigations. She has a history of mild asthma. What is the most appropriate next step in management?",
    "options": [
      "Prescribe a 10 day course of oral antibiotics.",
      "Recommend allergy testing.",
      "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
      "Obtain a sinus CT scan"
    ],
    "correct_answer_text": "Evaluate for other conditions such as asthma that might modify management and consider otolaryngology referral.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context emphasizes the importance of assessing patients with chronic rhinosinusitis (CRS) for multiple chronic conditions that could modify management, such as asthma. Given the patient's history of mild asthma and minimal improvement with current treatments, evaluating for other conditions and considering a referral to an otolaryngologist aligns with the recommendations provided in the context. Options A, B, and D do not directly address the need to evaluate and modify management based on the patient's existing conditions.",
    "reasoning_ground_truth": "Given her persistent symptoms and history of asthma, it is important to consider other comorbid conditions that can modify the management of her CRS. Allergy testing and a CT can be considered, but the primary step is to evaluate for other conditions, such as asthma. Antibiotics are not a standard treatment for CRS.",
    "context": "- Addition of asthma as a chronic condition that modifies management of chronic rhinosinusitis (CRS)\n- Three new key action statements on managing CRS that focus on polyps as a modifying factor, a recommendation in favor of topical intranasal therapy (saline irrigations, corticosteroids), and a recommendation against using topical or systemic antifungal agents\noption by 7 days after diagnosis or worsens during the initial management; (4) distinguish CRS and recurrent ARS from isolated episodes of ABRS and other causes of sinonasal symptoms; (5) assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia; (6) confirm the presence or absence of nasal polyps in a patient with CRS; and (7) recommend saline nasal irrigation,\n|10. CRS with polyps|The clinician should confirm the presence or absence of nasal polyps in a patient with CRS.|\n|11. Topical intranasal therapy for CRS|Clinicians should recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.|\n|12. Antifungal therapy for CRS|Clinicians should not prescribe topical or systemic antifungal therapy for patients with CRS.|\nCRS; and (7) recommend saline nasal irrigation, topical intranasal corticosteroids, or both for symptom relief of CRS.\nMultiple observational studies show that using a more aggressive treatment paradigm for CF patients with CRS, with regard to both maximizing surgery as well as postoperative medical therapy, can have a beneficial effect on the course of the sinus disease.199-202 Since CRS or recurrent ARS, especially if associated with nasal polyps, can be the first manifestation of CF, patients with polyps who present before age 18 years or have refractory rhinosinusitis should be screened for underlying CF.",
    "ground_truth_context": "Clinicians should assess the patient with CRS or recurrent ARS for multiple chronic conditions that would modify management, such as asthma, cystic fibrosis, immunocompromised state, and ciliary dyskinesia.",
    "is_correct": true
  },
  {
    "question": "A 70-year-old patient who underwent percutaneous coronary intervention (PCI) with a drug eluting stent (DES) 5 months ago for stable ischemic heart disease is currently on dual antiplatelet therapy (DAPT). He is scheduled for cataract surgery. What is the best way to manage his antiplatelet therapy?",
    "options": [
      "Continue both aspirin and clopidogrel for the surgery",
      "Stop both aspirin and clopidogrel 5 days before surgery",
      "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
      "Stop aspirin and continue clopidogrel during the surgery"
    ],
    "correct_answer_text": "Continue aspirin and stop clopidogrel 5 days prior to surgery.",
    "correct_answer_idx": 2.0,
    "model_answer": "C",
    "model_answer_idx": 2,
    "model_reasoning": "The context states that in patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that require discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor (in this case, clopidogrel) be restarted as soon as possible after surgery. Therefore, the best management for the patient scheduled for cataract surgery is to continue aspirin and stop clopidogrel 5 days prior to surgery, aligning with the recommendation to maintain aspirin therapy while temporarily holding the P2Y12 inhibitor.",
    "reasoning_ground_truth": "For patients with stable ischemic heart disease who are undergoing elective noncardiac surgery, guidelines recommend to continue aspirin and to stop the P2Y12 inhibitor, (clopidogrel) 5 days before surgery to balance the risks of bleeding and thrombotic events. Stopping both medications could lead to thrombotic events. Continuing both medications increases the bleeding risk.",
    "context": "surgery in patients treated with percutaneous coronary intervention (PCI) and DAPT supersede prior corresponding recommendations in the 6 relevant guidelines. These recommendations for duration of DAPT apply to newer-generation stents and, in general, only to those not treated with oral anticoagulant therapy.\nThe scope of this focused update is limited to addressing recommendations on duration of dual antiplatelet therapy (DAPT) (aspirin plus a P2Y12 inhibitor) in patients with coronary artery disease (CAD). Recommendations considered are those in 6 guidelines: \u201c2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention\u201d (9), \u201c2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery\u201d (10), \u201c2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients\n|I|C-EO|In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that mandate the discontinuation of P2Y12 inhibitor therapy, it is recommended that aspirin be continued if possible and the P2Y12 platelet receptor inhibitor be restarted as soon as possible after surgery.|\n|COR|LOE|RECOMMENDATIONS|\n|---|---|---|\n|I|A|In patients with STEMI treated with DAPT in conjunction with fibrinolytic therapy, P2Y12 inhibitor therapy (clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A) (140,142) and ideally at least 12 months (Level of Evidence: C-EO).|\n|I|B-NR|In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56\u201360,75\u201378).|\nThe magnitude of incremental bleeding risk in patients treated with antiplatelet therapy who undergo surgery is uncertain (157,158). If P2Y12 inhibitor therapy needs to be held in patients being treated with DAPT after stent implantation, continuation of aspirin therapy if possible is recommended, though this is based primarily on expert.  \nDownloaded From: http://content.onlinejacc.org/ by Lea Binder on 10/04/2016",
    "ground_truth_context": "For patients with SIHD who are undergoing elective noncardiac surgery, it is reasonable to continue aspirin and discontinue the P2Y12 inhibitor 5 days prior to surgery",
    "is_correct": true
  },
  {
    "evaluation_metrics": {
      "accuracy": 0.8395061728395061,
      "total": 81,
      "correct": 68,
      "confusion_matrix": {
        "Pred A": {
          "True A": 11,
          "True B": 3,
          "True C": 4,
          "True D": 0
        },
        "Pred B": {
          "True A": 1,
          "True B": 21,
          "True C": 1,
          "True D": 2
        },
        "Pred C": {
          "True A": 0,
          "True B": 1,
          "True C": 34,
          "True D": 0
        },
        "Pred D": {
          "True A": 1,
          "True B": 0,
          "True C": 0,
          "True D": 2
        }
      }
    }
  }
]